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Discussion of scholarly papers published on Ivermectin, starting from the article of Caly et al. in
Antiviral Research, available online April 3, 2020, and of some news that we can find about the use
of this drug for the treatment of Covid-19. A list of clinical trials is also given. The proposed
discussion was made in a series of versions from 14 June this of 29 July 2020.  For what concerns
scholarly papers, we report among them two preprints in MedRχiv. One,  posted on 10 June,
concludes that Ivermectin was associated with lower mortality during treatment of Covid-19.  The
other preprint, posted on 8 July, is showing the result of a clinical trial. This preprint tells, in its
conclusions that add-on use of Ivermectin is giving better results when compared to controls, in
particular a significant shorter hospitalization. A preprint, posted in Research Square on July 14, is
reported too. This preprint is giving the result of a trial regarding the combinations Ivermectin-
Doxycycline and Hydroxychloroquine-Azithromycin. Among news, we consider especially the
news regarding the use of Ivermectin in Peru. The case of Iquitos is discussed in detail. In Iquitos,
capital of the Department of Loreto, by May 25 Covid-19 cases and deaths had dropped notably, as
reported on the web. Epidemic data in this region are considered. Recent news (July 27), displaying
the observation of  rare symptoms of Covid-19, is also reported in detail. The observation was
related to a set of more than 3,000 patients in Lima. The formulation of Ivermectin used in Peru is
also discussed, in particular that of the oral solution, disclosed by the Peruvian Government. 
Torino, First version 14 June 2020 - Last version July 29, 2020 -  DOI 10.5281/zenodo.3893750
                                    ______________________________________________
1 - Introduction                                          
2 - The drug and the Nobel Prize   
3 - The trailblazer of the use of Ivermectin against onchocerciasis
4 - a) Scholarly Papers,  b) ChemRχiv, c) MedRxiv, d) Research Square preprints 
5 - Clinical trials regarding the use of Ivermectin for  Covid-19                                                  
6 - News from Bangladesh, Italy, US and Israel
7 - The problem of Surgisphere                                
8 - News from Peru and Bolivia
9 - The case of Iquitos (Peru)                                  
10 - A drug for humans
11 - Stabilized aqueous formulation 
12 - "There are no parenteral antihelminthic drugs licensed for use in humans"
13 - News propagation
14 - Discussion in TrialSite - A Health Movement
15 - Further news until 20 July and a report from Dr. T. Alam
16 - Not all doctors 
17 - US monopolises Remdesivir
18 - From Bulgary, India and Brazil
19 - a) SSRN or Antiviral Research, b) Un breve commento sul documento in SSRN, ora ritirato
20 - Rare symptoms of Covid-19 - a report from Dr. E. Durand, Lima
21 - Making ivermectin for oral use (6mg/mL)
1
22 - Data 
       Acknowledgement   -  Appendix   - References 
__________________
                         
Before reading this work, please consider that I am not a physician. I do not suggest the use of
ivermectin. I am not touting this drug. As previously told, the analysis of publications and news
about ivermectin is made in the framework of a wider investigation about information concerning
drugs used for Covid-19. 
_________________
1 - Introduction - In [SPA1], an article which is discussing the drugs used in Italy for the treatment
of Covid-19, we mentioned Ivermectin. In [SPA1], published on 9 May 2020, we reported the news
"Novità positive su Remdesivir e altri farmaci COVID-19/Farmaci",  dated 7 May and written by
Ernesto  Carafoli  and  Enrico  Bucci,  archived  http://archive.is/YdIqh  .  It  is  told  that  "L’ultimo
farmaco  giunto  sulla  scena  del  Covid-19  che  vale  la  pena  di  citare  è  l’Ivermectina:  un
antiparassitario noto per la sua attività antivirale a largo spettro usato anche in terapia umana per
affezioni dermatologiche.  Un interessante studio australiano ha dimostrato che la sua aggiunta a
cellule infettate con SARS_CoV-2 riduce in 48 ore il livello dell’RNA infettante di 5000 volte.
Tuttavia, bisogna considerare alcune obiezioni che sono state sollevate, prima di essere sicuri che
abbia senso iniziare dei trial su questo composto, come peraltro sembra si voglia fare in Francia".
That  is,  the  latest  drug  that  arrived  on  Covid-19  scene,  and  which  is  worth  mentioning,  is
Ivermectin. This drug is a pesticide known for its broad-spectrum antiviral activity and also used in
human therapy for  dermatological  diseases.  An interesting  Australian  study has  shown that  its
addition to SARS_CoV-2 infected cells reduces the level of infectious RNA in 48 hours by 5000
times. However, it is necessary to consider some objections that have been raised, before being sure
that it makes sense to start trials on this compound, as it seems to be done in France. 
Let us see the scholarly papers published until July 2020, on Ivermectin and some news,  that we
can find about its use for Covid-19.  For what concerns scholarly papers, among them we can find
two preprints in MedRχiv. One,  posted on 10 June,  concludes that Ivermectin was associated with
lower mortality during treatment of Covid-19.  The other preprint, posted on 8 July, is showing the
result of a clinical trial. This preprint tells, in its conclusions that add-on use of Ivermectin is giving
better results when compared to controls, in particular a significant shorter hospitalization. A further
preprint, posted in Research Square on July 14, is available too. This preprint is giving the result of
a trial regarding the combinations Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin.
Among news, we consider especially the news regarding the use of Ivermectin in Peru. The case of
Iquitos is discussed in detail. In Iquitos, capital city of the Department of Loreto, by May 25 Covid-
19 cases and deaths had dropped notably, as reported on the web. Epidemic data in this region are
considered. Recent news (July 27), displaying the observation of  rare symptoms of Covid-19, is
also reported in detail. The observation was related to a set of more than 3,000 patients in Lima. 
The aim of the discussion is to understand the different approach to Covid-19 treatment, based on
ivermectin, which is evident in Peru. In fact, the following discussion is made in the framework of
an investigation, which started from drugs used in Italy [SPA1-SPA9]. For what concerns the news,
in some cases, it has been preferred to left the original excerpt, to avoid misunderstanding. 
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2 - The Drug and the Nobel Prize - Before discussing literature and news relevant for the use of
Ivermectin in Covid-19, let us remember the extraordinary history of the drug.  Ivermectin is a drug
derived from avermectin. Actually, the term "avermectin" represents a series of drugs and pesticides
used to treat parasitic worms and insect pests. Its molecules are naturally occurring, being generated
as fermentation products by Streptomyces avermitilis, a soil actinomycete.  Half of the 2015 Nobel
Prize in Physiology or Medicine was awarded to William C. Campbell and Satoshi Ōmura, for
discovering avermectin, the derivatives of which have drastically lowered the incidence of river
blindness and lymphatic filariasis. The other half of the prize was awarded to Tu Youyou for her
discoveries concerning a novel therapy against Malaria. http://archive.is/JMRhi
About  ivermectin,  here what  is  told by WHO: "The treatment  for  onchocerciasis  is  ivermectin
(brand name Mectizan®). Unlike previous treatments, which had serious – sometimes fatal – side
effects, ivermectin is safe and can be used on a wide scale. It is also a very effective treatment, and
has single-handedly transformed the lives of millions of people suffering from onchocerciasis since
its introduction in 1987". https://www.who.int/apoc/cdti/ivermectin/en/ archived http://archive.is/FizVA . 
3 -  The trailblazer of the use of Ivermectin against onchocerciasis
In fact, Ivermectin was the new drug that "led to a revolutionary break-through in the late 1980s for
human  onchocerciasis  control"  [CUP1].  At  the  beginning  of  that  decade,  the  ivermectin  was
observed  as  being  "efficacious  against  the  microfilariae  of  Onchocerca  cervicalis,  a  common
parasite of horses. Of particular interest was that none of the ivermectin-treated animals exhibited
the gross or clinical reactions commonly associated with diethylcarbamazine treatment (Klei et al.,
1980). Using that finding, Aziz et al. (1982) [AZI1] conducted a preliminary clinical trial of 32
patients in Senegal infected with O. volvulus and found the drug to be efficacious and safe. This
seminal report led to a series of in-depth studies in Africa spanning 4–6 years aimed at determining
dosage efficacy, tolerance and possible effects on parasite transmission" [CUP1]. Among the main
results of these studies we find that ivermectin is highly tolerated and "therefore can be used in
mass drug administration programs". "Controlled clinical studies have indicated that a single oral
dose of ivermectin is safer and more effective therapy for onchocerciasis than the standard seven- to
10-day course of diethylcarbamazine" [AZI2]. As explained in [AZI3], the other drugs used against
onchocerchiasis have serious side effects, but ivermectin was highly tolerated. 
The "trialblazer" of the use of Ivermectin against onchocerciasis was Mohammed Abdul Aziz. " In
1981-1982,  Dr.  Mohammed Aziz  at  MDRL,  an  expert  in  River  Blindness,  conducted  the  first
successful human trial (Aziz et al., 1982) [AZI1]. The results were clear - patients given a single
dose  of  Ivermectin  showed either  complete  elimination  or  near  elimination  of  microfilariaload,
while the adult parasites were untouched" [NPM1].  The success of Ivermectin in clinical trials had
the following result.  In  1982,  Merck,  the producer  of  Mectizan®,  and WHO began a research
program, the Mectizan Donation Program, under the guidance of Mohammed Aziz and Kenneth
Brown, director of Merck's development of ivermectin for human use.
In  2015,  "A  Trailblazer  in  Medicine",  written  by  Leedy  Hoque,  https://www.thedailystar.net/op-
ed/trailblazer-medicine-179983 , gave a movingly memory of Dr. Aziz, Leedy's father. 
4 -a - Scholarly Papers
Here we consider the papers on ivermectin in relation to Covid-19. In the above-mentioned article
written by Carafoli and Bucci, it is told of an interesting Australian study concerning the drug. This
study is published in [CAL1] (available from Apr 3, 2020).
Ref. [CAL1] is the origin of researches, trials and use of Ivermectin for Covid-19. The authors -
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Caly, L., Druce, J., Catton, M., Jans, D. & Wagstaff, K. - tell that this drug, an FDA-approved anti-
parasitic,  which has previously shown to have broad-spectrum anti-viral  activity in vitro, "is an
inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h
post  infection  with  SARS-CoV-2  able  to  effect  ~5000-fold  reduction  in  viral  RNA  at  48  h.
Ivermectin  therefore  warrants  further  investigation  for  possible  benefits  in  humans".  The
authors are also telling that, "Ultimately, development of an effective anti-viral for SARS-CoV-2, if
given to patients early in infection,  could help to  limit  the viral  load,  prevent  severe disease
progression and limit person-person transmission". 
"The paper by Caly et al. has also elicited two letters to the editor," (Mike Bray, MD, Editor-in-
chief) The letters are printed in [BRA1], followed by the authors' response to both letters. [BRA1]
was  published  online  2020  Apr  21.  "Readers  should  be  aware  that  neither  the  letters  nor  the
response has been peer-reviewed, so appropriate caution should be used in quoting or citing them".  
Some objections concerning the use of Ivermectin for Covid-19 exist. We can find them given in
[SCH1].  In  the  abstract  it  is  told  that  "Caly,  Druce  [CAL1]  reported  that  ivermectin  inhibited
SARS-CoV-2 in vitro for up to 48 h using ivermectin at 5 uM. The concentration resulting in 50%
inhibition (IC50, 2 uM) was >35x higher than the maximum plasma concentration (Cmax) after oral
administration of the approved dose of ivermectin when given fasted". Authors of [SCH1] conclude
that "The likelihood of a successful clinical trial  using the approved dose of ivermectin is low.
Combination  therapy  should  be  evaluated  in  vitro.  Re-purposing  drugs  for  use  in  COVID-19
treatment is an ideal strategy but is only feasible when product safety has been established and
experiments of re-purposed drugs are conducted at clinically relevant concentrations".
In [CHO1], it is told that "potential drugs like hydroxychloroquine, ivermectin and azithromycin
have  been  tested  by  diverse  group  of  researchers  worldwide  for  their  potential  against  novel
coronavirus". The authors of [CHO1] are proposing a report  derived from the major researches
about  the  above-mentioned  drugs.  "Hydroxychloroquine  and  ivermectin  were  known to  act  by
creating  the  acidic  environment  and  inhibiting  the  importin  (IMPα/β1)  mediated  viral  import.
Azithromycin was found to act similar to the hydroxychloroquine as an acidotropic lipophilic weak
base. All the three categories of drugs seemed to potentially act against novel coronavirus infection.
However, their efficacies need to be studied in detail individually and in combination in-vivo in
order to combat COVID-19 infection".
Ref. [CHO1] illustrates the action of Ivermectin, as we can also find in Ref. [CAL1]. "SARS-CoV-2
(causative agent of COVID-19) is a single stranded RNA virus (positive sense) which is closely
related to SARS coronavirus (SARS-CoV). Recent study on ivermectin against SARS-CoV-2 under
in vitro conditions revealed that it can inhibit the viral replication. The single treatment of this drug
was able to reduce the virus up to 5000-fold in culture within 48h. However, no further reduction
was reported with further increase in time period i.e up to 72h. Moreover, no toxicity was seen with
the drug at any point of time" [CAL1]. "Mechanism by which ivermectin responded against the
CoV-19 virus is not known and was believed to be working similarly as it acted on other viruses. It
was known to inhibit the nuclear import of viral and host proteins. Integrase protein of viruses and
the importin (IMP) α/β1 heterodimer was responsible for IN nuclear import which further increases
the  infection.  As  most  of  the  RNA  viruses  are  dependent  upon  IMPα/β1  during  infection,
Ivermectin  acts  on  it  and inhibits  the  import  with  the  increase  in  antiviral  response"  [CAL1],
[JAN1]. 
In  Ref.  [SHA1]  the  authors  report,  as  [CAL1]  and  [CHO1],  that  the  "antiviral  potential  of
ivermectin  against  various viruses is  mediated  via the targeting of the following:  importin  α/β-
mediated nuclear transport of HIV-1 integrase and NS5 polymerase; NS3 helicase; nuclear import
of UL42; and nuclear localization signal-mediated nuclear import of Cap. As SARS-CoV-2 is an
RNA virus, the antiviral activity of ivermectin may be mediated through the inhibition of importin
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α/β-mediated nuclear transport of viral proteins. The clinical efficacy and utility of ivermectin in
SARS-CoV-2-infected patients are unpredictable at this stage, as we are dealing with a completely
novel virus".
In  [SHA1],  it  is  told  that  it  "has  also  been  hypothesized  that  combination  therapy  using
hydroxychloroquine and ivermectin may exert a synergistic inhibitory effect on SARS-CoV-2. In
this combination,  hydroxychloroquine acts by inhibiting the entry of SARS-CoV-2 into the host
cells,  whereas  ivermectin  further  enhances  the  antiviral  activity  by  inhibiting  viral  replication"
[PAT1].
In  [RIZ1],  we  find  an  article  proposing  "an  alternative  mechanism  of  action  for  this  drug
[Ivermectin] that makes it capable of having an antiviral action, also against the novel coronavirus,
in addition to the processes already reported in literature".
In [CHA1], the dosage of Ivermectin is considered. "Caly et al. report a 5,000-fold reduction in
SARS-CoV-2 RNA levels, compared with those in controls, after infected Vero/hSLAM cells were
incubated for 48 hours with 5 μM ivermectin. ... Pharmacokinetic studies in healthy volunteers have
suggested that single doses up to 120 mg of ivermectin can be safe and well tolerated. However,
even with this dose," which is quite greater than those approved by the US FDA we are "one order
of magnitude lower than effective in vitro concentrations against SARS-CoV-2. These findings may
seem to discourage follow-up clinical trials with ivermectin. However, some in vivo effect may be
possible even if efficacious in vitro concentrations are physiologically unattainable.  ...  Until  we
have a better understanding of ivermectin’s antiviral  mode of action and of appropriate in vitro
systems for testing,  we caution against  using findings in  Vero cells  as more than  a  qualitative
indicator of potential efficacy". The authors continue telling that they "believe the recent findings
regarding ivermectin warrant rapidly implemented controlled clinical trials to assess its efficacy
against  SARS-CoV-2.  These  trials  may  open  a  new  field  of  research  on  the  potential  use  of
avermectin antiparasitic drugs, including compounds with an improved pharmacokinetic profile, as
antivirals". The authors are pointing out some points, that need to be considered "before testing
ivermectin in severe disease". Three of the authors of [CHA1] are involved in trial [CHA2].
In [HEI1], abstract tells that "Ivermectin plays a role in several biological mechanisms, therefore it
could serve as a potential candidate in the treatment of a wide range of viruses including COVID-19
as well as other types of positive-sense single-stranded RNA viruses. In vivo studies of animal
models  revealed  a  broad  range  of  antiviral  effects  of  ivermectin,  however,  clinical  trials  are
necessary  to  appraise  the  potential  efficacy  of  ivermectin  in  clinical  setting".  Ref.  [HEI1]  is  a
systematic review of the antiviral effects of Ivermectin. "Several studies reported antiviral effects of
ivermectin on RNA viruses such as Zika, dengue, yellow fever, West Nile, ...  Furthermore, there
are some studies showing antiviral effects of ivermectin against DNA viruses". Playing a role in
several biological mechanisms, Ivermectin "could serve as a potential candidate in the treatment of
a  wide  range  of  viruses  including  COVID-19  as  well  as  other  types  of  positive-sense  single-
stranded RNA viruses. In vivo studies of animal models revealed a broad range of antiviral effects
of ivermectin, however, clinical trials are necessary to appraise the potential efficacy of ivermectin
in clinical setting".
In [ARU1],  we find  told  that  "There  are  many common observations  between  COVID-19 and
dengue. Elevated levels of ferritin, interleukin-6 (IL-6), vascular endothelial growth factor (VEGF),
D-dimer,  coagulopathy,  urticaria  and  ARDS  are  reported  in  both  diseases.  There  are  many
indicators that mast cell degranulation and histamine release may have a major role in COVID-19
and  dengue  severity.  Mast  cell  stabilizers,  antihistamines,  Vitamin  C,  HCQ,  azithromycin,
ivermectin may address different aspects of this cascade and thus reduce disease severity. Disease
mechanisms and immunopathology must  be  understood.  Focusing on anti-viral  action  of  drugs
alone could be counter productive. For example, CQ had no effect on viraemia but decreased cases
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of DHF".
"The in vitro antiviral activity end-points are analyzed from the pharmacokinetic perspective. The
available pharmacokinetic data from clinically relevant and excessive dosing studies indicate that
the SARS-CoV-2 inhibitory concentrations are not likely to be attainable in humans". This is told in
Ref. [MOM1].
In [ACH1], it is told that "Concerning the treatment outcome, adverse effect, and safety, Ivermectin
- Doxycycline combination is a better alternative to Hydroxychloroquine - Azithromycin therapy in
the case of mild to moderate degree of COVID19 patients. Though, both the treatment regimens
were found to be effective in this study" (On July 14, 2020, the same group of researchers [ACH1]
posted in Research Square the results of their clinical trial [ACH2]). 
According to [GON1], the results are the following. "The search of the databases led to the retrieval
of 25 articles. After the different phases of the selection process, eight articles were included in the
present review for the extraction of relevant data. The results suggest that ivermectin inhibits the
viral replication of SARS-CoV-2 through the action of the hypoxia-inducible factor (HIF-1α) and
consequent destabilization of importin α/β1 proteins. Conclusions tell that "Ivermectin inhibits the
viral  replication  of  SARS-CoV-2.  Laboratory  and  clinical  studies  are  needed  to  provide  more
evidence in terms of the best posology and possible associations with other drugs for combatting
COVID-19".
In [PAN1], authors tell that "Ivermectin acts by selectively binding to the glutamate-gated chloride
on channels of the parasite and leads to hyperpolarization of the cell which results in the paralysis
and death of the parasite". The anti-viral activity of ivermectin was first discovered with its ability
to block the interaction between the nuclear transport  receptor importin α/β(IMP) and integrase
molecule  of  HIV.  It  is  also  known to  block  the  viral  replication  of  host  of  viruses  including
influenza, flavivirus and dengue virus. ... A phase-III, double blind, randomized clinical trial has
been started with the aim to determine the safety and efficacy profile of the combination therapy of
hydroxychloroquine and ivermectin I  the treatment  of hospitalized COVD-19 patients"  (see the
Clinical Trial  https://clinicaltrials.gov/ct2/show/NCT04391127).
In [GUP1], we find a Letter to the Editor of The Brazilian Journal of Infectious Diseases,  entitled
"Ivermectin: potential candidate for the treatment of Covid 19". And a question is posed in [ECH1]:
Ivermectina: ¿La respuesta de Latinoamérica frente al SARS-CoV-2? 
Ref. [MOL1] contains a discussion which is necessary to read, in particular because of the news that
we will see in the following. A "word of caution is more than required and opportune specially for
the use of IVM [ivermectin]. Although available data are coming from front-line medical personnel,
and official sources, most of the evidences are based on entirely empirical facts". 
In Ref.  [WIJ1],  the authors are  reporting   "three  confirmed cases  of  COVID-19 infection  with
significant  improvement  clinically  and  radiologically  following  treatment  with  single  dose  of
ivermectin".
In [KUM1], a review is proposed, published 6 July. The abstract tells that "documentations serve as
a  ray  of  hope  for  considering  ivermectin  in  treating  COVID-19  due  to  its  suggested  nuclear
transport inhibitory mechanism". 
Other working papers  (see  Refs. [SCD1], [SCD2], [AGU1], [ORT1], [SHW1], [SOT1]) are given
in SSRN and Researchgate. 
For  what  concerns  Ivermectin  in  general,  I  strongly  suggest  the  reading  of  articles  [CRU1],
[CAM1],  [ACS1].  Let  us  add  also  [BUO1].  The  Background  of  the  article  is  the  following:
"Strongyloides  stercoralis  infection  is  a  neglected  condition  that  places  people  who  are
immunocompromised at risk of hyperinfection and death. Ivermectin is the drug of choice for the
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treatment of S stercoralis infection, but there is no definitive evidence on the optimal dose. This trial
aimed  to  assess  whether  multiple  doses  of  ivermectin  were  superior  to  a  single  dose  for  the
treatment of non-disseminated strongyloidiasis". Then, this article is important for what concerns
adverse effects of the drug. Authors tell that "Adverse events were generally of mild intensity and
more frequent in the multiple-dose than in the single-dose group. The trial was terminated early due
to futility".  Interpretation:  "Multiple  doses of ivermectin did not  show higher  efficacy and was
tolerated less than a single dose. A single dose should therefore be preferred for the treatment of
non-disseminated strongyloidiasis".
Then, as we have seen,  WHO tells that ivermectin is "safe and can be used on a wide scale", and
adverse effects are "generally of mild intensity and more frequent in the multiple-dose".  
From now on (that is, July 28, 2020), only scholarly articles with specific results and reporting on
the treatment of Covid-19 patients, will be added.
4 - b - ChemRχiv preprints
Let us consider two preprints in ChemRχiv. In [SEN1], 12 different COVID-19 targets are studied.
Among them, the RNA dependent RNA polymerase (RdRp) with RNA and Helicase NCB site
show the strongest affinity to Ivermectin amounting -10.4 kcal/mol and -9.6 kcal/mol, respectively.
"Molecular dynamics of corresponding protein-drug complexes reveals that the drug bound state of
RdRp with RNA has better structural stability than the Helicase NCB site, with MM/PBSA free
energy of -135.2 kJ/mol, almost twice that of Helicase (-76.6 kJ/mol). The selectivity of Ivermectin
to RdRp is triggered by a cooperative interaction of RNA-RdRp by ternary complex formation.
Identification of the target and its interaction profile with Ivermectin can lead to more powerful
drug designs for COVID-19 and experimental exploration".
Ref.  [MAU1] is  the  other  ChemRχiv  preprint.  It  is  discussing  the combination  Ivermectin  and
Doxycycline. As we will see from news, "in Bangladesh, a group of doctors reported astounding
success in treating patients suffering from COVID-19 with two commonly used drugs, Ivermectin
and Doxycycline". In [MAU1],  the author explored the possible mechanism by which the drugs
"might  have  worked  for  the  positive  response  in  the  COVID-19  patients".  To  explore  the
mechanism, molecular docking and the molecular dynamics simulations have been used. The study
"shows that both Ivermectin and doxycycline have significantly bind with SARS-CoV-2 proteins
but Ivermectin was better binding than doxycycline. Ivermectin showed a perfect binding site to the
Spike-RBD and ACE2 interacting region indicating that it might be interfering in the interaction of
spike  with ACE2 and preventing  the viral  entry  in  to  the host  cells.  Ivermectin  also exhibited
significant  binding  affinity  with  different  SARS-CoV-2  structural  and  non-structural  proteins
(NSPs) which have diverse functions in virus life cycle. ... Thus, our docking and simulation studies
reveal that combination of Ivermectin and doxycycline might be executing the effect by inhibition
of viral entry and enhance viral load clearance by targeting various viral functional proteins".
4 - c - MedRχiv preprints
Let us conclude the review of scholarly articles on the use of Ivermectin in Covid-19 patients with
two preprint in MedRχiv. 
In  [RAJ1],  the  authors  conclude  that  "Ivermectin  was  associated  with  lower  mortality  during
treatment of COVID-19, especially in patients who required higher inspired oxygen or ventilatory
support. These findings should be further evaluated with randomized controlled trials". Objective of
[RAJ1]:  "To  determine  whether  Ivermectin  is  associated  with  lower  mortality  rate  in  patients
7
hospitalized with COVID-19". Design and Setting are: "Retrospective cohort study of consecutive
patients hospitalized at four Broward Health hospitals in South Florida with confirmed SARS-CoV-
2. Enrollment dates were March 15, 2020 through May 11, 2020. Follow up data for all outcomes
was May 19, 2020. Participants: 280 patients with confirmed SARS-CoV-2 infection (mean age
59.6 years [standard deviation 17.9], 45.4% female), of whom 173 were treated with ivermectin and
107 were usual care were reviewed".
In [GOR1], the results of the clinical trial NCT04343092C have been proposed (see the next section
for all the clinical trials available at ClinicalTrials.gov). The preprint was posted on July 08, 2020.
Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial), by Faiq I.
Gorial et al. , preprint in MedRχiv. 
From the  Abstract.  In  vitro,  studies  indicated  that  ivermectin  (IVM)  has  antiviral  effect.  The
researchers made the clinical trial to assess the effectiveness of ivermectin (IVM) as add-on therapy
to hydroxychloroquine (HCQ) and azithromycin (AZT) in treatment of COVID-19. "Methods: This
Pilot  clinical  trial  conducted  on  hospitalized  adult  patients  with  mild  to  moderate  COVID-19
diagnosed according to WHO interim guidance. Sixteen Patients received a single dose of IVM
200Mcg /kg on admission day as add on therapy to hydroxychloroquine (HCQ) and Azithromycin
(AZT)  and were  compared  with  71  controls  received  HCQ and AZT matched  in  age,  gender,
clinical features, and comorbidities. The primary outcome was percentage of cured patients, defined
as symptoms free to be discharged from the hospital  and 2 consecutive negative PCR test from
nasopharyngeal swabs at least 24 hours apart. The secondary outcomes were time to cure in both
groups and evaluated by measuring time from admission of the patient to the hospital till discharge.
Results: Of 87 patients included in the study, the mean age ± SD (range) of patients in the IVM
group was similar to controls ... Majority of patients in both groups were male but statistically not
significant ... All the patients of IVM group were cured compared with the controls [ 16 (100 %) vs
69  (97.2  %)].  Two  patients  died  in  the  controls.  The  mean  time  to  stay  in  the  hospital  was
significantly lower in IVM group compared with the controls (7.62 ±2.75 versus 13.22 ±.90 days,
p=0.00005, effect size= 0.82). No adverse events were observed Conclusions : Add-on use of IVM
to HCQ and AZT had better effectiveness, shorter hospital stay, and relatively safe compared with
controls. however, a larger prospective study with longer follow up may be needed to validate these
results".
4 - d - Research Square preprints
On July 14,  2020,  the  same authors of [ACH1] posted in  Research Square the results  of  their
clinical  trial  [ACH2].  In  their  study,  the  authors  "investigated  and  compared  outcomes  of
Ivermectin-Doxycycline  vs.  Hydroxychloroquine-Azithromycin  combination  therapy  COVID19
patients with mild to moderate disease". Patients with mild to moderate COVID-19 disease were
tested positive by RT PCR for SARS-CoV-2 infection. "Patients were divided randomly into two
groups: Ivermectin 200µgm/kg single dose + Doxycycline 100 mg BID for 10days in group A, and
Hydroxychloroquine 400 mg 1st day, then200mg BID for 9days + Azithromycin 500 mg daily for 5
days in group B". "All subjects in the Ivermectin-Doxycycline group (group A) reached a negative
PCR for SARS-CoV-2, at a mean of 8.93 days, and all reached symptomatic recovery, at a mean of
5.93 days, with 55.10% symptom-free by the 5th day. In the Hydroxychloroquine-Azithromcyin
group (group B), 96.36% reached a negative PCR at a mean of 6.99 days and were symptoms-free
at 9.33 days. Group A patients had symptoms that could have been caused by the medication in
31.67% of patients, including lethargy in 14(23.3%), nausea in 11(18.3%), and occasional vertigo in
7(11.66%) of patients.  In Group B, 46.43% had symptoms that could have been caused by the
medication,  including  13(23.21%)  mild  blurring  of  vision  and  headache;  22(39.2%)  increased
lethargy and dizziness, 10(17.85%) occasional palpitation, and 9(16.07%) nausea and vomiting".
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According  to  the  researchers,  "Ivermectin-Doxycycline  combination  showed  a  trend  toward
superiority to the Hydroxychloroquine-Azithromycin combination therapy in the case of patients
with mild to moderate COVID19 disease, though the difference in time to becoming symptom-free
and the difference in time to negative PCR was not statistically significant".
5 - Clinical trials regarding the use of Ivermectin for  Covid-19   
On July 28, 2020, we can find 33 clinical trials reported by ClinicalTrials.gov , at the following link
https://clinicaltrials.gov/ct2/results?cond=COVID&term=ivermectin+&cntry=&state=&city=&dist=
For other trials about drugs for Covid-19, see [SPA4]. 
In the following list, the date is that when the trial was first posted on ClinicalTrials.gov .
1)  13 April 2020 -  Efficacy of Ivermectin as Add on Therapy in COVID19 Patients - Drug:
Ivermectin (IVM) - Locations: General Directorate of Medical City, Bagdad, Baghdad, Iraq -
https://ClinicalTrials.gov/show/NCT04343092
2)  4 May 2020 - Max Ivermectin - COVID 19 Study Versus Standard of Care Treatment for
COVID 19 Cases. A Pilot Study -   Drug:  Ivermectin -    Locations: Max Super Speciality
hospital,  Saket  (A  unit  of  Devki  Devi  Foundation),  New  Delhi,  Delhi,  India  -
https://ClinicalTrials.gov/show/NCT04373824
3) 19 May 2020 - Efficacy of Ivermectin in COVID-19 -   Drug:  Ivermectin 6 MG Oral
Tablet (2 tablets) -   Locations: Combined Military Hospital Lahore, Lahore, Punjab, Pakistan
- https://ClinicalTrials.gov/show/NCT04392713
4) 27 May 2020 - Ivermectin and Doxycycine in COVID-19 Treatment   -   Drug: Ivermectin,
Doxycycline,   Chloroquine  -  Locations:  Sherief  Abd-Elsalam,  Tanta,  Egypt  -
https://ClinicalTrials.gov/show/NCT04403555
5) 9 June 2020 - Prophylactic Ivermectin in COVID-19 Contacts - Drug: Ivermectin Tablets -
Locations:  Zagazig  University,  Zagazig,  Sharkia,  Egypt  -
https://ClinicalTrials.gov/show/NCT04422561
6) 11 June 2020 -   Ivermectin In Treatment of COVID 19 Patients - Drug: Ivermectin -
Locations:  isolation  and  referal  hospitals  for  COVID  19  patients,  Cairo,  Egypt  -
https://ClinicalTrials.gov/show/NCT04425707
7) 17 April 2020 -   The Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment -
Drug: Chloroquine, Nitazoxanide, Ivermectin -   Locations:  Tanta University, Tanta, Egypt  -
https://ClinicalTrials.gov/show/NCT04351347
8) 22 May 2020 -  Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy
for COVID-19 -    Drug: Ivermectin, Azithromycin, Cholecalciferol -   Locations: Outpatient
treatment, Mexico City, Mexico - https://ClinicalTrials.gov/show/NCT04399746
9)  11 May 2020 -   Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-
19 -   Drug: IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus
standard care. CONTROL arm will receive standard care. -   Locations: Centro de Educación
Médica  e  Investigaciones  Clínicas  "Norberto  Quirno"  CEMIC,  Buenos  Aires,  Ciudad  De
Buenos Aires, Argentina - https://ClinicalTrials.gov/show/NCT04381884
10)   5  May  2020  -   Trial  to  Promote  Recovery  From  COVID-19  With  Ivermectin  or
Endocrine Therapy -  Drug: Bicalutamide 150 Mg Oral Tablet|Drug: Ivermectin 3Mg Tab -
Locations:    Johns  Hopkins  Hospital,  Baltimore,  Maryland,  United  States  -
https://ClinicalTrials.gov/show/NCT04374279
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11)  24 April 2020  -     Ivermectin and Nitazoxanide Combination Therapy for COVID-19 -
Combination  Product:  Ivermectin  plus  Nitazoxanide,  Other:  Standard  Care  -
https://ClinicalTrials.gov/show/NCT04360356
12)  18 May 2020 -   New Antiviral Drugs for Treatment of COVID-19 - Drug: Treatment
group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of
seven days -   Locations: Mansoura University, Mansoura, Select A State Or Province, Egypt
-    https://ClinicalTrials.gov/show/NCT04392427
13)   16 June 2020 -   A Comparative Study on Ivermectin and Hydroxychloroquine on the
COVID19  Patients  in  Bangladesh  -  Drug:  Ivermectin  +  Doxycycline  |  Drug:
Hydroxychloroquine + Azithromycin -   Locations:    Chakoria  Upazilla  Health Complex,
Cox's Bazar, Bangladesh -  https://ClinicalTrials.gov/show/NCT04434144
14)    12 June 2020 -   Ivermectin vs. Placebo for the Treatment of Patients With Mild to
Moderate COVID-19 -    Drug: Ivermectin Oral Product -   Locations:    Sheba Medical
Center, Ramat-Gan, Israel -      https://ClinicalTrials.gov/show/NCT04429711
15)   18 May 2020 -  Hydroxychloroquine and Ivermectin for the Treatment of COVID-19
Infection -    Drug: Hydroxychloroquine, Ivermectin, Placebo -   Locations:  Jose Manuel
Arreola Guerra, Aguascalientes, Mexico -     https://ClinicalTrials.gov/show/NCT04391127
16)  28 May 2020 -  Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19
- Drug: Ivermectin Oral Product, Placebo -   https://ClinicalTrials.gov/show/NCT04405843
17) 29 May 2020 -  Efficacy and Safety of Ivermectin and Doxycycline in Combination or
IVE Alone in  Patients  With  COVID-19 Infection.  -   Drug:  Ivermectin  +  Doxycycline  +
Placebo,  Ivermectin + Placebo, Placebo -     https://ClinicalTrials.gov/show/NCT04407130
18)  15 May 2020 -   Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial -      Drug:
Ivermectin,  Placebo  -  Clinica  Universidad  de  Navarra,  Pamplona,  Navarra,  Spain  -
https://ClinicalTrials.gov/show/NCT04390022
19)  17 June 2020 -  Ivermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs
(ART)  Among  Asymptomatic  COVID-19  -  Drug:  Ivermectin  Pill,  Combined
ART/hydroxychloroquine -   Locations:  Siriraj Hospital, Bangkok Noi, Bangkok, Thailand -
https://ClinicalTrials.gov/show/NCT04435587
20)  29 May 2020 - Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With
SARS-CoV-2  With  or  Without  Symptoms  -  Drug:  Ivermectin,  Placebo  -
https://ClinicalTrials.gov/show/NCT04407507
21)   11 May 2020 -  Novel Regimens in COVID-19 Treatment -    Drug: Nitazoxanide,
Ivermectin,  Chloroquine,  Azithromycin - https://ClinicalTrials.gov/show/NCT04382846
22)  11 June 2020 -  IVERMECTIN Aspirin Dexametasone and Enoxaparin as Treatment of
Covid 19 -  Drug: Ivermectin 5 MG/ML -   Locations:  Hospital Eurnekian, Buenos Aires,
Argentina  - https://ClinicalTrials.gov/show/NCT04425863
23)   11  June  2020  -  USEFULNESS  of  Topic  Ivermectin  and  Carrageenan  to  Prevent
Contagion  of  Covid  19  -    Device:  iota  carrageenan,  Ivermectin  -   Locations:  Hospital
Eurnekian, Buenos Aires, Argentina - https://ClinicalTrials.gov/show/NCT04425850
24)   5 May 2020 - Novel Agents for Treatment of High-risk COVID-19 Positive Patients -
Drugs:  Hydroxychloroquine|,  Hydroxychloroquine  and Azithromycin,  Hydroxychloroquine
and Ivermectin, Camostat Mesilate -   Locations:   University of Kentucky Markey Cancer
Center, Lexington, Kentucky, United States -  https://ClinicalTrials.gov/show/NCT04374019 
25)   14 June 2020 - A Real-life Experience on Treatment of Patients With COVID 19 - Drug:
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Chloroquine,  Favipiravir, Nitazoxanide, Ivermectin, Niclosamide, Other drugs -   Locations:
Tanta university hospital, Tanta, Egypt  - https://ClinicalTrials.gov/show/NCT04345419 
26)  16 June  2020 -  A Study to  Compare  the  Efficacy  and Safety  of  Different  Doses  of
Ivermectin for COVID-19 -  Drug: Ivermectin, Other: Standard treatment for COVID-19 -
Locations:   Hospital Univeristário da Universidade Federal de São Carlos (HU-UFSCar), São
Carlos, São Paulo, Brazil -  https://ClinicalTrials.gov/show/NCT04431466  
27)    19 June 2020 - COVidIVERmectin: Ivermectin for Treatment of Covid-19 -  Drug:
Ivermectin - Other: Placebo -   Locations: IRCCS Sacro Cuore Don Calabria hospital, Negrar,
Verona,  Italy,  Policlinico  S.  Orsola,  Bologna,  Italy,  Ospedale  Luigi  Sacco,  Milan,  Italy,
Ospedale di Rovereto,  Rovereto,  Italy,  Ospedale Amedeo di Savoia, Turin,  Italy,  Hospital
Clinic/ISGlobal,  Barcelona,  Spain,  Hospital  La  Paz-Carlos  III,  Madrid,  Spain  -
https://ClinicalTrials.gov/show/NCT04438850 
28)  24 June 2020 -  Ivermectin in Treatment of COVID-19 -  Drug: Ivermectin -  Locations:
Waheed Shouman, Zagazig, Sharkia, Egypt  - https://ClinicalTrials.gov/show/NCT04445311
29)  25 June 2020 -  Early  Treatment   With  Ivermectin  and  LosarTAN  for  Cancer
Patients  With  COVID-19  Infection.  Drugs:  Placebo,  Ivermectin,  Losartan  -
https://ClinicalTrials.gov/show/NCT04447235
30)   24 June 2020 - A Preventive Treatment for Migrant Workers at High-risk of Covid-19 -
Interventions:   Drug:  Hydroxychloroquine  Sulfate  Tablets,   Ivermectin  3Mg Tab,   Zinc  ,
Povidone-Iodine  -  Dietary  Supplement:  Vitamin  C  -  Locations   Tuas  South  Dormitory,
Singapore -      https://ClinicalTrials.gov/show/NCT04446104
31) 24 June 2020 - Anti - Androgen Treatment for COVID-19 -  Interventions:     Drug:
Dutasteride  -  Drug:  Ivermectin  -  Drug:  Azithromycin  -  Locations:  Corpometria  Institute,
Brasilia, Brazil -   https://ClinicalTrials.gov/show/NCT04446429
32)  7  July  2020  -  Worldwide  Trends  on  COVID-19  Research  After  the  Declaration  of
COVID-19  Pandemic  -  Drugs:  Convalescent  Plasma  Transfusion,  Hydroxychloroquine,
DAS181,  Ivermectin,  Interferon Beta-1A -    https://ClinicalTrials.gov/show/NCT04460547
33) 15 July 2020 - Efficacy of Subcutaneous Ivermectin With or Without Zinc and Nigella
Sativa in COVID-19 Patients - Drug: Nigella Sativa / Black Cumin , Ivermectin Injectable
Solution, Other: Placebo ,  Zinc - Location  Shaikh Zayed Hospital, Lahore, Punjab, Pakistan
-   https://ClinicalTrials.gov/show/NCT04472585
6 - News from Bangladesh, Italy, US and Israel
Let us start for news coming from  Bangladesh.  https://worldhealth.net/news/ Anti Aging News -
May 25, 2020 - Bangladesh Medical Team Claims Ivermectin With Doxycycline Clears COVID-19
- Archived http://archive.is/wh6uE - "A Bangladeshi medical team is claiming that their research on
the combination of two widely used and common drugs has yielded positive results  in clearing
COVID-19 patients with acute symptoms of the disease.  "We have got astounding results. Out of
60 COVID-19 patients,  all  recovered  as  the combination  of  the two drugs were  applied",  said
Professor Dr Md Tarek Alam, the head of medicine department  at  private Bangladesh Medical
College  Hospital  (BMCH).  According  to  Alam  who  is  a  reputed  clinician  in  Bangladesh  the
antiprotozoal  medicine  Ivermectin in combination with one dose of the antibiotic  Doxycycline
yielded the results of COVID-19 patients being cleared as being negative from the disease". 
UNB NEWS DHAKA PUBLISH- JUNE 06, 2020, 06:21 PM UNB NEWS - UPDATE- JUNE 07,
2020,  10:35  AM  -  Covid-19:  BMCH  physician  reports  ‘amazing  results’  using  Ivermectin,
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Doxycycline. It is not the patients who decide the medication,  says Dr Tarek Alam - Archived
http://archive.is/A2rc2 - "Physicians from Bangladesh Medical College Hospital (BMCH), led by Dr
Tarek Alam, claimed that  a  combination  of the  anti-parasitic  drug ‘ivermectin’  with antibiotic
‘Doxycycline’ yielded amazing results against Covid-19".
https://www.thedailystar.net/ 12:00 AM,  June 14, 2020 / LAST MODIFIED: 08:43 AM, June 14,
2020 - Use of  Ivermectin: Hope held out, caution called for - Archived http://archive.is/Hup01 -
"Physicians at a Dhaka hospital claimed they have observed "cumulative efficacy" of ivermectin in
Covid-19 patients while using the drug in combination with doxycycline. They said although they
were yet to be certain about the exact efficacy of the drug combination, they would seek permission
from Bangladesh Medical and Research Council (BMRC) for a clinical trial to know further about
its effectiveness."
The combination of ivermectin and doxycycline is used for the treatment of other diseases (see for
instance  [HOE1], [BAZ1]). Then, we have the proposal of a combination hydroxychloroquine and
ivermectin.
From  Italy -  https://www.trialsitenews.com/university-of-naples-federico-ii-physicians-hypothesize-why-
not-try-hydroxychloroquine-ivermectin-in-combo-against-covid-19/ May  3, 2020-  Archived
http://archive.is/yFsuG "University  of  Naples  Federico  II  Physicians  Hypothesize:  Why Not  Try
Hydroxychloroquine  &  Ivermectin in  Combo  Against  COVID-19?"   -  "Two  researchers  /
physicians out of the University of Naples Federico II — one of the oldest universities in the world
— introduce the use of two drugs classically used by dermatologists for the investigational use in
fighting SARS-CoV-2, the virus behind the COVID-19 pandemic. The two doctors hypothesize that
the  use  of  Hydroxychloroquine (HCQ)  and  Ivermectin may  evidence  a  consequential  and
synergistic  action  if  administered  simultaneously  both  for  chemoprophylaxis  and  treatment  of
COVID-19". Physicians are Dr. Angela Patri and Dr. Gabriella Fabbrocini. 
https://www.stampareggiana.it - 8 Aprile 2020 - Una novità importante è che oggi al San Raffaele
inizia  anche   la  sperimentazione  di   un  nuovo  farmaco,  l’Ivermectina.  Archived
http://archive.is/tqnX7   -  "Il  suo  utilizzo  [Ivermectina]   è  stato  approvato  in  via  sperimentale
dall’AIFA, l’ente Italiano del farmaco". Dopo l'annuncio della sua efficacia in vitro, "Adesso si
ricerca la conferma clinica, si tratta di un farmaco da tempo usato contro la scabbia, i vermi ed altre
malattie  prodotte  da  parassiti  la  cui  specifica  modalità  di  azione  è  stata  chiarita.   Aumenta  la
concentrazione di cloro  all’interno delle cellule che hanno specifici recettori, Covid 19 compreso.
Questo fatto determina la paralisi  e poi la morte  del virus. Ora resta la rapida sperimentazione
clinica autorizzata in Italia essendo uno dei paesi più colpiti".
Then,  news  from  US.  https://www.newsmax.com/us/  -  Breakthrough  Drug:  Ivermectin Shows
'Astounding' Results Against Coronavirus - By David A. Patten    |   Friday, 22 May 2020 11:16
PM - Archived  http://archive.is/uqrxr - "Doctors have administered the drug ivermectin in several
simultaneous trials in several countries sometimes in combination with other common medications.
Physicians who participated in the study report that patients’  viral loads began declining almost
immediately  after  they  began  administering  ivermectin,  a  widely  available  prescription  drug
approved to combat parasites, scabies and head lice. ... Emergency medical physician Dr. Peter H.
Hibberd,  M.D.,  of Palm Beach County,  Florida,  told Newsmax Friday evening in an exclusive
interview that he’s optimistic the drug will prove to be an important therapeutic advance, although
he  expects  more  trials  will  be  needed  before  it  wins  FDA  approval  for  use  as  a  COVID-19
medication.  He noted it  has impressed doctors in clinical trials  on multiple  continents.  In some
cases, doctors reported just one dose of ivermectin markedly improved a patient’s condition. U. S.
patients received a single oral dose, and some of them received a booster dose seven days later. The
FDA-approved dose for parasitic infections was used. ... On Thursday, a team of U.S. doctors led
by Dr.  Jean-Jacques Rajter  at  the Broward Health  Medical  Center  in  Fort  Lauderdale,  Florida,
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submitted findings to an institutional review board. According to a medical source familiar with the
study, some 250 coronavirus patients were involved in the Broward trial. The results were dramatic,
with “statistically significant improvement in mortality,” according to the source".
About  the  mentioned  trial,  see  https://www.trialsitenews.com/broward-county-doctor-using-ivermectin-
off-label-combo-on-covid-19-patients-it-is-working-secures-county-health-protocol-approval/ Archived
http://archive.is/IQSts  (See Ref. [RAJ1]).
From Israel - https://www.jpost.com/- Israeli researcher: Antiparasitic drug could 'cure' coronavirus -
JUNE 15, 2020  - Archived http://archive.is/HADqB - "Prof. Eli Schwartz launched a clinical trial of
the drug Ivermectin, a broad-spectrum antiparasitic agent that has also been shown to fight viruses.
A tropical disease expert is testing a drug used to fight parasites in third-world countries that he said
could help reduce the length of infection for people who catch coronavirus, enabling them to go
back to work and life in as little as a few days. ... "At the onset of this virus, everyone was talking
about the anti-malaria drug,” he said, referring to hydroxychloroquine, which was first touted by US
President  Donald  Trump,  but  has  since  been  linked  to  increased  risk  of  death  in  coronavirus
patients, among other health risks. “We decided to look more widely for other medications and
considered a few drugs that might have antiviral activity,” he said; Ivermectin was selected".
https://www.trialsitenews.com/ -  In  Pursuit  of  Real-World  Ivermectin Stories:  Tales  from
Pathanamthitta JUN 17, 2020 - http://archive.is/iWQu6
https://www.trialsitenews.com/ - 100-Year-Old Discharged from Mumbai’s Rajawadi Hospital after
Successful  Ivermectin  Treatment  -  JUN  18,  2020-  http://archive.is/hkuON -  "Now  apparently
commonly in use in India, the medics at Rajawadi Hospital report that Ivermectin was the drug that
actually worked, leading to the recent discharge of 100 year old Mr. Mali. It was to the thrill of all
the staff to see this patient heal rapidly". 
7 - The problem of Surgisphere - https://www.the-scientist.com/ - 16 June 2020 - Surgisphere Sows
Confusion About Another Unproven COVID-19 Drug - "The company behind a now-discredited
study  on  hydroxychloroquine  also  posted  a  report  that  has  been  cited  by  Latin  American
governments recommending ivermectin as a possible coronavirus treatment. Clinicians there say the
effects have been extremely damaging". http://archive.is/G6JM6 .
This article  is  telling  "One of the most  influential  studies on ivermectin’s  effect  in COVID-19
patients  was  a  large  observational  study  that  used  a  database  owned  by  Surgisphere,  a  now-
discredited Illinois-based company founded by vascular surgeon Sapan Desai. That study, published
on the preprint server SSRN in early April and updated a couple weeks later, reported a strong
positive association between ivermectin treatment and COVID-19 patient survival, and has been
cited  in  white  papers  and  reports  by  Latin  American  health  researchers  and  governments  as
evidence of the drug’s efficacy". The paper in SSRN is no more available1. About it, see please the
discussion  by  Carlos  Javier  Chaccour  (he  is  running  a  clinical  trial  about  ivermectin).
http://archive.is/d0VOd 
www.the-scientist.com/ is  highlighting  in  the  web  page  the  following:  "With  ivermectin  firmly
entrenched in political and public minds as a weapon against the pandemic, the question of evidence
is now of secondary importance for some members of the medical and scientific communities".
Even if mitigated by a "some members", this is a serious accusation against these communities. Let
us observe that the sentence of the-scientist concerning ivermectin, that is "firmly entrenched in
political  and  public  minds  as  a  weapon  against  the  pandemic",  could  have  been  applied  to
1 As told in the introduction, the aim of this discussion is to understand the different approach to Covid-19 treatment, 
based on ivermectin, currently running mainly in Peru. in the framework of an investigation, which started from 
drugs used in Italy. It is not the discussion of SSRN paper for sure.  For it, see  Chaccour 's web article.
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hydroxychloroquine  too,  the  "Trump's  'miracle'  drug",  as  defined  in  The  Guardian,
http://archive.is/ToTIv . About this drug, "Praised by presidents", see "Three big studies dim hopes
that  hydroxychloroquine  can  treat  or  prevent  COVID-19",  Jun  9,  2020,  in  Science,
http://archive.is/oVg7I  .
8 - News from Peru and Bolivia
Let us continue with news - Fron CNN in Spanish -  https://cnnespanol.cnn.com/ -  Ivermectina, el
arma sin validación científica que se usa en Bolivia para tratar covid-19 - Por Gloria Carrasco, CNN
Publicado a las 16:23 ET (20:23 GMT) 29 mayo, 2020 Archived http://archive.is/17R1Y - "Bolivia
incluyó a la ivermectina dentro de la lista de medicamentos esenciales para que pueda ser usada en
el tratamiento de pacientes con covid-19. En el departamento de Beni, en el norte del país, hay una
campaña para distribuir  gratuitamente  este  medicamento  entre  los  pobladores  del  municipio  de
Trinidad".
https://cnnespanol.cnn.com/ -  17:17  ET(21:17  GMT)  10  Junio,  2020  -  Perú  da  impulso  a
hidroxicloroquina e ivermectina como tratamiento para covid-19 - Por Kiarinna Parisi Archived
http://archive.is/w8KLw -  Bolivia autoriza  el  uso  de  ivermectina  contra  covid-19  3:53  -  "El
Ministerio de Salud de Perú (Minsa) dio impulso como tratamiento para el nuevo coronavirus a dos
medicamentos  que  carecen  de  autorización  por  parte  de  autoridades  sanitarias  o  de  consenso
científico sobre su eficacia y seguridad para pacientes de covid-19. ... Por su parte, la ivermectina es
un  agente  antiparasitario  de  amplio  espectro,  aprobado  por  la  Administración  de  Medicinas  y
Alimentos de Estados Unidos para ciertos usos en humanos y animales, aunque la prevención o
tratamiento  contra  el  coronavirus  no  es  uno  de  ellos.  A  principios  de  mayo,  dicha  autoridad
desaconsejó su uso asociado al covid-19 tras afirmar que se necesitaban más estudios al respecto".
12/6/2020 https://www.eleconomistaamerica.pe/  "El  hospital  de San Juan de Lurigancho empezó a
elaborar ivermectina para cubrir la demanda existente de este medicamento por parte de pacientes
afectados  por  la  COVID-19,  que  llegan  al  nosocomio  que  pertenece  a  la  Dirección  de  Redes
Integradas  de  Salud  (Diris)  Lima  Centro,  informó  el  Ministerio  de  Salud".   Archived
http://archive.is/hak3F
https://exitosanoticias.pe/ - 13/6/2020 Dr. Fernández: “Si más peruanos tomaran ivermectina, habría
menos casos de COVID-19” - Usar la Ivermectina es como ponerte un chaleco antibalas contra la
enfermedad. En el Perú, más de 1 millón de personas la consumen, y nadie se ha muerto”, indicó.
Archived  http://archive.is/fusra -  ¿Qué hace  la  Ivermectina  en  el  cuerpo? "Evita  que  el  virus  se
multiplique en las células. Por eso, la  Ivermectina y la Hidroxicloroquina trabajan muy bien en
casos iniciales o cuando recién comienza la enfermedad”.
https://www.marca.com/claro-mx/ - 11/6/2020 - Hidroxicloroquina e ivermectina: ¿por qué llevan la
delantera contra  el  coronavirus? "Por su parte,  Marcelo Navajas,  Ministro de Salud de Bolivia,
emitió un permiso para la aplicación de la Ivermectina en los humanos para tratar el Covid-19 en
dicho país, aunque aclaran que su uso contra el coronavirus no está avalado por la Organización
Mundial de la Salud."  -------------- web.archive.org/web/20200614112908/https://www.marca.com/claro-
mx/trending/2020/06/11/5ee18c6d268e3eaf4b8b45a9.html
https://www.connuestroperu.com/ - Miscelánea  12 Junio 2020 - La Libertad producirá 150 mil dosis
de ivermectina para luchar contra el coronavirus - El Gobierno Regional de La Libertad producirá
150 mil  dosis  de  ivermectina para  combatir  el  coronavirus  COVID-19 en los  pacientes  leves.
Archived http://archive.is/BKf8q
Here also a direct experience by Dr. A. Camargo -  https://www.connuestroperu.com/ - An interview
with Dr. Antonio Camargo,  02 Junio 2020 - Archived http://archive.is/Cy8Wc . "Usted contrajo la
enfermedad  y  se  curó  con  ivermectina,  ¿podría  narrarnos  su  experiencia?  Me infecté  en  mis
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actividades  laborales,  atendiendo pacientes  oncológicos.  Un paciente que buscó ayuda y estuvo
buen tiempo en nuestro centro contagió a dos trabajadoras y la trabajadora de limpieza me infectó.
El diagnóstico de mi infección fue realizado el 8 o 9 de mayo. Tenía una carga viral terriblemente
alta,  como  para  hacer  una  especie  de  patrón  de  vigilancia.  Tengo  un  laboratorio  de  biología
molecular y recuerdo que el biólogo me dijo que mi carga viral era muy alta. Hasta ese momento no
sentía nada, sólo una resequedad en la garganta, sin tos ni malestar general ni fiebre, pero sabía que
se venía un “tsunami” sobre mí. Allí decidí probar en mí lo que estaba probando en otros pacientes.
De inmediato tomé 60mg por día de ivermectina, acompañando con hidroxicloroquina: 200 mg
por la mañana y 200mg por la noche, más 200mg de sales de zinc por día, que son dosis altas. Ese
fue el tratamiento coronicida. A las 48 horas me realicé un control con PCR, test molecular para
controlar mi carga viral y no había carga viral en mi faringe, no había virus".
In  this  interview,  Dr.  Camargo  is  reporting  his  experience  and  the  use  of  ivermectin,
hydroxychloroquine and zinc. 
9 - The case of Iquitos (Peru)
This is a specific case which deserves a detailed discussion, because we can be sure that a large use
of Ivermectin has been made. It is therefore very important for any possible statistical analysis.
https://www.connuestroperu.com/ - 13/6/2020 "El verdadero Comando COVID-19 de Iquitos: médicos
independientes lograron contener el azote del coronavirus, no el Minsa ni Essalud"  - Archived
http://archive.vn/ePtmg
"Desde fines de abril a mayo las escenas diarias en los hospitales de Iquitos eran de avalancha de
infectados con el coronavirus COVID-19, que sobrepasaron su capacidad y muchos pacientes no
podían ser atendidos, mientras que otros hasta morían en los exteriores. ... Es gracias a los médicos
independientes que Iquitos superó el desastre que causó la pandemia, que ahora está controlada,
pues de no contener  a muchísimos pacientes  en sus domicilios  con estos tratamientos exitosos,
todos ellos habrían muerto". Interview by Con Nuestro Perú with Dr. Sergio Bardon, "uno de los
médicos independientes que participaron en esta lucha y fueron el verdadero Comando COVID-19
en Iquitos". 
Question:  "Desde  abril  y  mayo hay  un  número  creciente  de  médicos  que  usan  exitosamente
ivermectina, habiendo una cura. ¿A qué atribuye que internacionalmente no se difunda ello y se
prefiera a fármacos que tienen menor efecto? Answer; "Con respecto a la ivermectina lo que se ha
visto es que ha bajado en muchísimos pacientes la carga viral, es decir, la cantidad de virus que una
persona tiene en el cuerpo, y por lo tanto, va a mejorar su cuadro clínico y disminuir drásticamente
las posibilidades de que la persona se complique la infección viral".
Dr. Bardon tells also: "Lo cierto es que somos muchos los médicos que estamos usando ivermectina
con muchísimo éxito. Por supuesto, estos medicamentos tienen mayor éxito cuanto antes se recetan
y cuanto menos síntomas tiene el paciente, porque cuando llega a una fase de complicación aguda,
con una disnea importante, allí ya empiezan a actuar muchas otras cosas que no son necesariamente
la carga viral, porque es la respuesta inflamatoria que tiene cada paciente. Entonces la ivermectina
ya  no  tiene  mucho  sentido,  por  eso  es  importante  no  solamente  darla  sino  darla  a  tiempo  ...
Efectivamente, el éxito que he tenido con ivermectina es mucho. En general, a partir del tercero o
cuarto día ya en la gran mayoría de los pacientes no se han visto síntomas ni signos de COVID-19,
y con respecto a la negativización de la prueba, se obtiene también rápidamente a partir de una
semana. ...  Estoy tratando a todos los pacientes en forma ambulatoria.  Solamente uno tuvo que
recibir  internamiento,  que  fue  el  primero.  De  allí  todos  han  sido  seguidos  ambulatoriamente,
especialmente porque trato pacientes en Amazonas, Loreto, en lugares donde ni siquiera tienen la
posibilidad  de  ir  a  un  hospital  y  estamos  manejándolo  básicamente  con  la  asociación  de
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ivermectina-azitromicina, y hasta ahora todos han sido exitosos".
As it is evident from previous news, in Iquitos the ivermectin was used. Iquitos is the capital of
Peru's Maynas Province and Loreto Region. It is the largest metropolis in the Peruvian Amazon,
east of the Andes,  and it is the ninth most populous city of Peru.
In [FRA1], it was told that the health system in this town was subjected to a very high stress for
Covid-19. "The first COVID-19 case in the Peruvian Amazon, detected on March 17, seemed to be
a one-off — a tour guide who apparently caught it from foreign visitors. Within weeks, however,
Carlos  Calampa  [Regional  Health  Director]  saw patients  overflowing  into  the  corridors  of  the
Loreto Regional Hospital in Iquitos, where he was director". After describing the situation in the
town and Peru,  the article  [FRA1] ends telling  "By May 25,  COVID-19 cases  and deaths  had
dropped in Iquitos but were rising in remote areas accessible only by river or light plane, Calampa
said. He is reinforcing staff and coordinating with the military to deliver medicine, oxygen, and
other supplies to health centres on the Marañón, Corrientes, and Tigre rivers, where much of the
population is Indigenous".
It seems that something happened  before May 25.  And in fact, in the article of  June 8, 2020,
entitled "Effective formula knocks out Covid-19 in the Peruvian Amazon", by  Juan J Chamie
https://medium.com/@juanjchamie/effective-formula-knocks-out-covid-19-in-the-peruvian-amazon-
150565e9b6c6 archived http://archive.is/pI5x6 , we find the proper question "How did they get through
it so quickly?". "The numbers don’t lie. While the coastal departments (Sí Covid) haven’t stopped
the growing number of reported deaths, the main departments in the jungle region (Ex-Covid), for
example in Loreto and Ucayali, broke the trend and within three weeks drastically lowered the rise
in mortality rates. Although they still need more time to reach normal values, the trend indicates
that they’ll manage it very soon". - And then: How did they get through it so quickly? - The author
of the article in Medium tells that the "drop in deaths in the region is attributed to the general use of
a medication, and that without even having scientific evidence, according to local residents, it has
saved many lives". The drug is Ivermectin.
"In mid-April, a group of volunteers initiated a campaign in the department of Ucayali to deliver
ivermectin to residents. They openly acknowledged that they were using veterinarian ivermectin
and confirmed positive results, as well. ... Similarly, in the city of Iquitos ... an independent group
of volunteer doctors initiated a public campaign plus free vaccinations with ivermectin".  This is
told in medium.com.
As we have seen in news published by  www.connuestroperu.com, there are physicians such a Dr.
Bardon  that,  in  medical  clinics,  are  administrating  the  drug  under  their  medical  supervision.
However, there are also different experiences, based on groups of volunteers, that used the drug in
the veterinary formulation.  Here news in  http://www.perulactea.com/ on 16/05/2020 -  "En Iquitos
vienen aplicando Ivermectina de uso veterinario con buenos resultados frente a Covid19". Archived
http://archive.is/yx24r
"La dosificación que se está utilizando es 1ml x 2 días. Una botella de 1000 ml Ivermecticina al 1%
de uso en ganadería, se consigue en 130 soles en las veterinarias. En pocas palabras con 130 soles
se pueden inyectar a 500 personas. [1 Sol equals 0.26 Euro] Se afirma que ya atendieron más de
2000  personas  con  este  tratamiento,  quedando  claro  que  la  Ivermectina  está  dando  resultados
favorables para pacientes covid 19 en etapas 1 y 2. ... Desde el día martes 12 de mayo se esta
aplicando la inyección de IVERMECTINA a personas con síntomas leves de Covid 19, la atención
será totalmente GRATUITA". The article tells that the dosage of the drug that is being used is 1ml x
2 days.  A bottle  of 1000 ml Ivermectin at  1% of use in livestock,  is  available  in 130 soles in
veterinary medicine. In short, with 130 soles, 500 people can be injected. It is stated that more than
2000 people have already been treated with this treatment, making it clear that Ivermectin is giving
favorable results for covid 19 patients in stages 1 and 2. Since Tuesday, May 12, the Ivermectin
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injection is being applied to people with mild symptoms of Covid 19, the care will be totally for
free. 
Let us stress once more. A large use of ivermectin has been made in this province of Peru. It would
be very interesting to have further reports about the results of the treatment, besides the report
mentioned above.
For  the  moment,  about  the  Department  of  Loreto,  we  can  show  data  from
https://bing.com/covid/local/loreto_peru?vert=graph
Fig.1 - Red dots represents the confirmed cases, the black dots the victims of the virus. Data from 16 April to 26 July.
Fig.2 - Daily new cases in Loreto, on the left- https://bing.com/covid/local/loreto_peru?vert=graph. On the right, the
purple curve represents data from Loreto, the blue curve from Callao.
The number of victims in Loreto was 259 (20 May), 288 (20 June), 368 (20 July). The last number
is 544. Then, in Loreto the percentage of fatal cases was: 544/10721=0.05 , that is 5%  . What could
we deduce from the graph and numbers, about a possible effect of ivermectin? It is difficult, and we
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need  further  investigation.  However,  the  curve  of  the  confirmed  cases  seems  to  approach  the
plateau. 
The image given previously (on the right) shows the comparison of cases in Loreto and Callao,
which is much more densely populated than Loreto. It seems that in Loreto, the curve is closer to
the plateau than in Callao. From https://coronalevel.com/Peru/Loreto/ , the following plot is available.
Data: Johns Hopkins University CSSE. Data from 29 May to 28 July.
Fig.3  - Data from Johns Hopkins University CSSE.
20  June  2020 -  https://ojo-publico.com/1909/medicos-piden-cautela-en-uso-de-hidroxicloroquina-e-
ivermectina - archived http://archive.is/Vdy90 - "Juan Carlos Celis Salinas es médico infectólogo en el
hospital regional de Loreto, en donde las últimas semanas han atendido a cientos de personas con
Covid-19 y a muchas otras que han llegado con síntomas de haberse automedicado con ivermectina,
un fármaco usado como parte del tratamiento experimental contra el Sars-Cov-2 y que necesita un
acompañamiento  clínico.  “Hay personas  que  llegan  luego  de  haber  tomado  dosis  excesivas  de
ivermectina,  y  otros  que  se  aplican  la  de  uso  veterinario;  en  ambos  casos  llegan  con  efectos
adversos. Llegan con mareos, taquicardia”, sostiene".
The drug must be used under  medical supervision.
10 - A drug for humans
About the concerns of using a drug involved in veterinary use, an answer was the following.  “La
Ivermectina fue creada para el tratamiento de humanos” - El médico trujillano Gustavo Elera ha
frenado en seco al coronavirus en unos mil 200 pacientes en Chanchamayo con este fármaco, muy
empleado en medicina veterinaria". http://www.laindustria.pe/nota/16073-la-ivermectina-fue-creada-para-
el-tratamiento-de-humanos - dated 7 June 2020 - Archived http://archive.is/beTgM
"Desde abril a la fecha, el médico Gustavo Elera Arévalo, trujillano él, ha tratado con excelentes
resultados a mil 200 pacientes, todos en su momento afectados por el coronavirus, en La Merced,
Chanchamayo,  Junín".  In  this  article,  the  reporter  asks  Dr.  Elera  about  the  difference  between
Ivermectin for human and veterinary use. Question: "En el mercado encontramos la Ivermectina
para uso humano y animal. La de uso humano ha escaseado y las pocas que se encuentran, tienen un
costo muy elevado. Así las cosas, ¿se puede emplear la veterinaria?" Answer: "Claro. No es tóxica.
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Nosotros hemos utilizado la de uso veterinario para el penal de La Merced (Chanchamayo), para la
Policía Nacional, para todos los pacientes que estamos viendo sin ningún problema y la vamos a
utilizar en el barrido que haremos en algunos otros sectores del mismo Chanchamayo. La diferencia
entre la Ivermectina de uso humano y la de uso veterinario es que la de uso humano es Ivermectina
más  agua  y  Sorbitol,  que  es  un  saborizante  que  la  vuelve  dulce,  y  la  de  uso  veterinario  es
Ivermectina más agua y punto".
We can find Ivermectin in the formulation for human and veterinary use. The formulations for
human use are in short supply and at a very high cost. So, a question is "Can we use veterinary
medicine?" Elera's answer is the following: "Sure. It is not toxic. We have used the formulation for
veterinary use for the  ... The difference (in  the formulation) of Ivermectin for human use and for
veterinary  use  is  the  following.  The  formulation  for  human  use  is  Ivermectin  plus  water  and
Sorbitol, which is a flavouring that makes it sweet. The formulation  for veterinary use is Ivermectin
plus water, plain and simple.  Elera' answer is translated because, in a following sections, the two
formulations of ivermectin will be discussed in detail.
Let us stress that it is necessary to check carefully the formulations, and avoid self-medication (the
use of drugs needs medical supervision). At this is clear because of different concentrations. "El
médico veterinario Eleazar Vargas señaló que la ivermectina que viene siendo usada para humanos
difiere en concentración del empleado para animales". 18 Junio, 2020 - http://archive.is/1qN3N
Dr. Eleazar Vergas is dean of the Colegio Médico Veterinario. Let us report some sentences from
this article “Hay una sola ivermectina, que se dedique para animales o para humanos ya es un tema
de concentración. Aunque creo que para humanos lo utilizan solo de vía oral”, señaló el experto a
Exitosa. It is also told, "Por otro lado, el decano del Colegio Médico Veterinario hizo un llamado a
los  médicos  a  respetar  la  profesión  veterinaria,  luego  que  se  generaran  algunos  comentarios
despectivos de algunos de ellos respecto a los puntos de vista de veterinarios sobre la ivermectina:
“creo que es una contraposición inoportuna, no es momento para decir yo soy más o yo soy menos.
He escuchado que incluso hablan del veterinario de forma despectiva, no debería ser así. Nosotros
somos profesionales de la salud”.
We  can  find  further  information  about  the  use  of  ivermectin  in  Peru  in  the  recent
https://elcomercio.pe/tecnologia/ciencias/ivermectina-gustavo-elera-ivermectina-el-medico-que-se-ha-
convertido-en-el-referente-nacional-de-una-campana-anticovid-19-que-carece-de-base-cientifica-noticia/   -
26 June 2020. Ivermectina -  El rostro de una campaña contra el COVID-19 que crece en el Perú
pero que no tiene base científica -  El  médico Gustavo Elera impulsa el  uso de ivermectina en
diversas regiones del país con el apoyo de alcaldes. Pese a la opinión de expertos, asegura tener la
evidencia suficiente para ello". In the article, we find that Gustavo Elera is preparing an article to be
submitted to Lancet, where he will describe the results of the use of ivermectin. It is also stressed
that "En  diversos  medios  regionales,  el  médico  [Elera]  ha  defendido  el  uso  de  ivermectina
veterinaria en lugar de la fabricada para humanos, con el argumento de que la primera es mucho
más barata. Ha asegurado, además, que “la de uso veterinario es Ivermectina más agua y punto”.
The article  continues  telling "Pero  especialistas  consultados  por  este  Diario  advirtieron  que  su
consumo puede traer efectos secundarios y que bajo ninguna circunstancia un medicamento para
animales debe ser usado en humanos".
And  a  link  is  given:   https://elcomercio.pe/tecnologia/ciencias/coronavirus-ivermectina-covid-19-en-
ucayali-autoridades-reparten-ivermectina-para-animales-para-tratar-pacientes-con-coronavirus-noticia/?
ref=ecr/ -  dated  26 May 2020, where it is told that "Dos consejeros regionales, uno de ellos del
partido Alianza para el Progreso, publicitan su iniciativa como “un acto filantrópico”. Sin embargo,
expertos subrayan que la medicina veterinaria puede ser nociva en humanos".  The article has the
title: COVID-19 | Autoridades reparten ivermectina para vacas para tratar pacientes con coronavirus
en Ucayali". Veterinary medicine is a branch of medicine, working with drugs, like the ivermectin,
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which can have formulations both for humans and animals.  "Although the majority of veterinary
dosage forms contain the same drug as human dosage forms, some veterinary preparation contain
drugs that are not widely used in humans. ... Some types of dosage forms are suitable for used in
humans  and  certain  animal  species.  They  include  parenteral  solution;  conventional  tablets  and
capsules; oral solution and suspensions" [RAM1].
Then,  like  many  other  drugs,  ivermectin  is  not  only  a  drug  "para  vacas".  The  highlight  of
elcomercio.pe  is therefore misleading. In any case,  we find there a discussion about the different
formulations.
“[La presentación para animales] podría tener ivermectina como principio activo, pero no se sabe
qué más tiene. Esos otros componentes son los que pueden producir efectos no deseados”, explica
Alfonso Zavaleta, profesor de Farmacia y Bioquímica de la Universidad Peruana Cayetano Heredia
(UPCH).  ...  El  modo  de  aplicación  en  humanos  es  oral,  mientras  que  en  los  animales  es
intramuscular. ... Ricardo Grandez, profesor de la Facultad de Medicina Veterinaria y Zootecnia de
la UPCH, alerta que si se administra esta droga por vía subcutánea e intramuscular y “se aplica
inadecuadamente, puede producir necrosis en la zona de aplicación”. “La presentación inyectable
[usada en animales] es de larga duración, tiene sustancias que liberan lentamente el principio activo.
Algunos  de  estos  productos  podrían  generar  reacciones  en  algunos  individuos  o  en  todos  los
individuos".
Actually,  for  animals  too,  it  is  necessary  to  be  careful  and in  fact,  it  is  told  "Dosis  y  vía  de
administración: ...  Vía subcutánea (S. C.) únicamente".,  as at the web page of  this  company
https://www.vecol.com.co/productos/veterinaria/antiparasitarios/ivermectina-1,  http://archive.is/YAEVk .
See also https://www.ema.europa.eu/en/documents/referral/bovimectin-injection-article-33-referral-annex-i-
ii-iii_it.pdf  . For veterinary use, subcutaneous injections2 are the proper route of administration for
aqueous solutions,  as  we will  see  in  the  next  section.  Novel  oil  formulations  can  be  used  for
intramuscular injection too. Let us add also that it is true that ivermectin for humans is in the form
of tablets, but we have case reports about the use of subcutaneous ivermectin too, as a safe salvage
therapy [PAC1],[BAR1]. 
11 - Stabilized aqueous formulation
Gustavo Elera tells that the drug for veterinary use is  "Ivermectina más agua y punto”. Of course,
as soon as we can read the report that he promised we will know the specific drug, the dosage, and
the route of administration. However, we have to note the following.  In Ref. [KSH1], which is
discussing about ivermectin for veterinary use, it is told that "Ivermectin is generally insoluble and
unstable in aqueous preparations. Hence, to overcome the problem of poor water solubility and
obtain a stable injectable  formulation of ivermectin,  several commercial  preparations have been
developed which use organic solvents as vehicles". High concentrations of organic solvents have
been reported to induce significant side effects [DON1], and pain and inflammation at the injection
site were commonly observed side effects of commercial  ivermectin preparations [FRO1]. "The
commercially available ivermectin preparations employ different vehicles that help in stabilizing
the compound".
Table 1 of [KSH1] is giving details. One of the formulations,  for parenteral and oral routes of
administration,  is  the  following.  "Stabilized  aqueous  formulation containing  0.1-7.5%  w/v
ivermectin (Parenteral administration) with other components such as surface active agent – 0.5-
2.5%  (polyoxyethylene  sorbitan  monoisostearate,  polyoxyethylene  sorbitan  monostearate,  and
polysorbate  80).  Cosolvent  –  10-60% (glycerol  formal,  glycerin,  and  polyethylene  glycol)  and
Substrate  – 1-5% w/v (benzyl  alcohol,  lidocaine,  parabens,  and choline)".  The solubilization of
2 Subcutaneous and intramuscular injections are different techniques of injection.
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ivermectin  in  water  is  described in  the patent  (Inventors Pak-Kan A.  Lo ,  James B. Williams,
Merck  and  Co  Inc),  https://patents.google.com/patent/US4389397A/en .  Abstract:  "Ivermectin,  an
antiparasitic  agent  which is  insoluble  and unstable  in  water,  is  solubilized  by the formation of
colloidal particles, called micelles, with surface active agents as solubilizers and stabilized by using
cosolvents and/or appropriate substrates in the aqueous formulation. The liquid formulations are
suitable for use as parenteral or oral administration for the treatment of parasitic infections".
In [KSH1], among the several formulations for veterinary use, in the Table 1, we can find also the
following:  "Subcutaneous  and intramuscular  administration  of  a  novel  oil-based  formulation  of
ivermectin was found to be superior to the commercially available standard preparation" [LIF1].
12 - "There are no parenteral antihelminthic drugs licensed for use in humans"
Since  we  are  talking  about  ivermectin  for  veterinary  use  by  means  of  a  parenteral  route  of
administration, we have also to add an important observation.  In [MAR1], it is told that "There are
no parenteral antihelminthic3 drugs licensed for use in humans. [The authors of [MAR1]] report the
successful treatment of disseminated strongyloidiasis with a parenteral veterinary formulation of
ivermectin  in  a  patient  presenting  with  severe  malabsorption  and  paralytic  ileus.  To [authors']
knowledge,  ivermectin  levels  are  reported  for  the  first  time  in  this  situation".  The  year  of
publication of the article is 2005. In [ROG1], a book of 2010, it is stressed that patients "who are
unable to absorb oral therapy present a difficult challenge as no parental preparations" of ivermectin
are licensed for use in human. However, parenteral ivermectin exists and it is that for animals. 
The  same,  that  is  that  "At  present  there  are  no  parenteral  anthelminthics  licensed  for  use  in
humans",  is  also  told  in  [BAR1],  an  article  published  in  2016.  And  in  2020,  "Regarding  the
treatment, oral ivermectin is recommended for uncomplicated strongyloidiasis and is usually well-
tolerated with a higher cure rate than with albendazole.  In patients with hyperinfection,  and no
available  oral  route,  therapeutic  options  are  limited.  No  parenteral  anti-helminthic  drugs  are
licensed for use in humans, but parenteral ivermectin is used in veterinary medicine. Although drug-
related toxicity, parenteral ivermectin has been used in humans as rescue therapy, appearing to be
effective and safe" ([CIP1], and references therein). 
It seems to me that the only parenteral ivermectin is that for veterinary use. The use of it in rescue
therapy is effective and safe, according to publications. If this ivermectin can be the proper bullet
for Sars-Cov-2, why not use it? 
13 - News propagation
As we have seen, in the region of Iquitos, Peru, physicians in their clinics used, under their control,
ivermectin.  However,  there  were also some volunteers,  in  particular  an evangelical  group,  that
treated people having Covid-19 symptoms, with ivermectin for veterinary use. 
"Un grupo evangélico peruano inyecta  un medicamento veterinario a miles  de personas para la
covid-19". This is the title of an article in El Pais that started a sequence of news.  "En Nauta, al
menos 5.000 personas  la  han  recibido  [ivermectin]”,  cuenta  Leonardo Tello,  director  de Radio
Ucamara, la principal emisora de la ciudad ubicada a dos horas de la capital de la región, Iquitos".
https://elpais.com/sociedad/2020-06-19/un-grupo-evangelico-peruano-inyecta-un-medicamento-veterinario-
a-miles-de-personas.html  dated 19 June 2020, archived http://archive.is/l4IhL .
"Tello cuenta que muchas personas sintieron el aceleramiento del corazón tras recibir la inyección.
“Ha sido horroroso el efecto secundario”, relata. El director de Radio Ucamara explica que algunos
3 Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms and other internal
parasites from the body by either stunning or killing them and without causing significant damage to the host. 
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pastores evangélicos de Loreto han vinculado al nuevo coronavirus con el demonio y el fin del
mundo, ofreciendo esas inyecciones “como una salvación”. El Pais continues explaining that "En la
comunidad de Cuninico, donde gran parte de la población tenía síntomas de la covid-19, el técnico
del  módulo  de  salud  ...  dijo  a  los  voluntarios  de  las  denominadas  Misiones  Evangélicas  de la
Amazonía, que ya no necesitaban la “vacuna” porque la mayoría de personas se estaba cuidando
con  la  medicina  tradicional,  con  plantas.  Sin  embargo,  los  enviados  por  el  grupo  evangélico
decidieron administrar  la ivermectina veterinaria.  "La explicación de los voluntarios fue clara y
directa de que está aprobado mediante una ley, y que es un tratamiento animal que da resultados
positivos  como  vacuna”,  refirió  el  apu  –jefe  indígena–  de  Cuninico,  Wadson  Trujillo  Acosta.
“Dijeron que lo están haciendo a nivel nacional y también en Nauta, y alertaron de los efectos
secundarios como la diarrea. A algunas personas sí les produjo esa reacción”, describió".
Adverse effects were observed, and this is due to the dose of the drug. Ivermectin is safe, if used in
the proper manner, under the control of a physician.  For the side effects of accidental self-injection
and ingestions of injectable solutions, see please what is reported in the  web page on ivermectin at
http://www.inchem.org/documents/pims/pharm/ivermect.htm archived http://archive.is/awBXE . 
In any case, it is clear from El Pais that Tello and Acosta are giving two different versions, and that
the behaviour of the evangelical group (or better, of some of the members of the group) was wrong.
Let  us  see  how  the  SUN  reduces  the  text:   https://www.thesun.co.uk/news/11934870/sick-amazon-
evangelicals-animal-drug-coronavirus-ivermectin/ archived  http://archive.is/IIxsF
"He [Tello]  said that many of those  who had  received the treatment had suffered an increase in
their heart rate whilst others have warned of diarrhoea as a side effect."  The  SUN  is  reporting
only  what  was  told  by  Tello.  From the  SUN,  we can  see  a  further  propagation  in  Italy.  The
information  was  proposed  by  the  Messaggero  in  the  following  article
https://www.ilmessaggero.it/mondo/coronavirus_farmaco_animali_amazzonia_indigeni_ultime_notizie_24_
giugno_2020-5307039.html ,  dated  24 June  2020,  archived  http://archive.is/3wAic in  the  following
manner: "Leonardo Tello, direttore della stazione radio locale Radio Ucamara, racconta: «Gli effetti
collaterali sono stati terribili:  attacchi cardiaci, diarrea e molto altro»." That is: Leonardo Tello,
director  of  the  local  radio  station  Radio  Ucamara,  says:  «The  side  effects  were  terrible:  heart
attacks, diarrhea and much more».
This is not what Tello told to El Pais, and it is also quite different from what is told in the SUN.
Nobody died after having received the drug. And this is clear form the news in El Pais. 
14 - Discussion in TrialSite - A Health Movement
An interesting  discussion  is  given  in  the  article  "How a  Grassroots  Health  Movement  Led  to
Acceptance of Ivermectin as a COVID-19 Therapy in Peru",  https://www.trialsitenews.com/how-a-
grass-roots-health-movement-led-to-acceptance-of-ivermectin-as-a-covid-19-therapy-in-peru/ ,  12  June
2020, archived http://archive.is/e9t8k - The discussion is published in TrialSite News, a  digital media
dedicated to the coverage of clinical research and clinical trials, investigators and pharma. A section
is devoted to Ivermectin. Here the link https://www.trialsitenews.com/category/ivermectin/ . 
"Perhaps Peru is the epicentre of the movement for off-label use of Ivermectin to treat COVID-19
patients.  The  doctors  there  swear  by  it.  In  fact,  some  of  them  curse  the  government  for  not
embracing the anti-parasite drug sooner as they believe more lives could have been saved. ... This
grassroots medical movement for Ivermectin as a treatment for COVID-19 in many ways has been
driven out of Peru as the story continues to unfold".
The web page tells that "For many weeks now, TrialSite News researchers heard a greater number
of stories about the use of Ivermectin in both Bolivia and Peru". And also "TrialSite News has
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interviewed  doctors  around  the  world  using  the  anti-parasitic  drug  to  treat  COVID-19  with
significant success. ... an informal network of many doctors around Peru drove a kind of community
movement to use the medicine to treat COVID-19. The government came to the conclusion that a
sufficient number of experts in that country had formed a consensus that couldn’t be ignored".  
TrialSite News tells that university-based documents exist, "floating around in Peru that may have
led  to  the  off-label  use  and,  ultimately,  the  approval".  A title  is  given  "Therapeutic  Plan  that
includes  Ivermectin  in  the  First  Line  of  Action"  (see  https://archive.vn/aCprF  ).  To  my  best
knowledge,  no document is available  in English.    Gustavo A. Aguirre-Chang seems to be the
author  of  the  document  entitled  "INCLUSIÓN  DE  LA  IVERMECTINA  EN  LA  PRIMERA  LÍNEA  DE
ACCIÓN TERAPÉUTICA PARA COVID-19. Se reporta una muy significativa disminución de la Tasa de
Letalidad  con su uso".  Lima,  Perú.  2 de Mayo del  2020. Available  at   https://megalabs.global/ -
http://archive.is/x12Co .  In  the  paper,  the  author  is  telling  that  "Por  su  parte,  en  República
Dominicana,  el  Médico  Neumólogo  J.  Tavares  reporta  que  va  tratando  247  pacientes  con
Ivermectina con respuesta favorable en todos los casos y no ha manifestado ningún caso fatal. De
manera similar, a nivel local, si bien a la fecha aún no son muchos los casos documentados, la Tasa
de Letalidad  viene siendo 0% y además se observa que en el  100% de los  casos  tratados  con
Ivermectina se presenta una mejoría de la enfermedad y resolución de la fiebre dentro de las 48
horas de iniciado el tratamiento". Aguirre-Chang is detailing of 82 cases in Peru4. 
The TrialSite is also telling that Gustavo A. Aguirre-Chang, in mid May, commented in a Reddit
group "that his group had treated 39 COVID-19 cases and that the Ivermectin regimen was quite
successful for “those who complete the indicated treatment and undergo medical follow-up.” Dr.
Aguirre-Chan reported that 1) patients with the disease were showing improvement within 2 and 3
days of starting treatment (100% of the 36); 2) fever resolution rate at 36 hours of taking ivermectin
was at 94% and 3) resolution rate of dyspnea (difficulty breathing) at 72 hours was 86%."
Let us continue with the discussion in TrialSite. In Peru, "Doctors went about using Ivermectin and
reporting on positive results to colleagues. Conservative forces there resisted noting, after all, this
drug was for animals".  "For Animals: Humans Need Not Try. ... the first line of defense against
this drug, at least in the developed “first world,” was that Ivermectin was an “animal drug.” This
sort of bias was evidenced clearly by the FDA’s Ivermectin warning. Titled “FAQ : COVID-19 and
Ivermectin Intended for Animals,” the FDA took overt advantage of a loaded headline to convey an
underlying point. ...  But did they think anyone would take them seriously? But it was Created for
Humans.  In  reality,  Ivermectin  was  in  fact  created  for  humans.  In  Peru,  doctors  are  treating
COVID-19 patients with one drop every 24 hours for two days and many physicians report within a
month they see patients fully recovered".  We have discussed before the formulations for humans
and veterinarian use.
TrialSite  tells  that  "Prominent  researchers  and industry  observers  were  obviously skeptical  and
downplayed the Monash findings5, arguing that studies in humans weren’t feasible due to dosage
and other factors".  As we have seen, many scientists and physicians are running 33 clinical trials
with ivermectin.  TrialSite continues: "However, in nations that struggle with poverty and lack of
access  to more  expensive drugs,  such as  remdesivir,  physicians  had to  chart  their  own course.
Hence, dozens if not hundreds of doctors around the world are prescribing ivermectin in COVID-19
patients;  Peru  perhaps  can  be  considered  the  epicentre  of  that  movement.  TrialSite  News  has
interviewed a handful of these doctors and they all  report the same thing: that the anti-parasite
drug ... actually works better than remdesivir. This finding is heard from doctors all over the world;
TrialSite  News has interviewed physicians  in  Bangladesh,  France,  India,  Brazil  and the United
4 Aguirre-Chang is also reporting the interest of MedinCell for an injectable formulation of ivermectin, see 
https://www.trialsitenews.com/medincell-continues-its-investigational-pursuit-of-ivermectin-targeting-covid-19-
patients/ 
5 That is, the results reported in [CAL1]. 
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States not to mention Peru, Bolivia and Mexico. ... TrialSite News recently interviewed a contact in
Peru,  a  PhD in  Public  Administration  and Computer  Science,  that  happens to  be active  in  the
Ivermectin movement there. He reports that in the city of Iquitos, a place known for scary tropical
diseases, the widespread use of Ivermectin has led to a steep drop in the number COVID-19 cases".
As we have seen, we can find news telling that there is a large use in Peru of ivermectin. In the
TrialSite  it  is  stressed  that  the  use  of  this  drug  is  linked  to  a  health  movement,  which  has
government support. When compared to the number of physicians in the world, the "dozens if not
hundreds of doctors around the world" is a small number, but it important to know, when possible,
their experiences in specific reports, in particular for the case of Iquitos. 
15 - Further news until 20 July and a report from Dr. T. Alam
Trafficking drugs:  a problem related to pandemic. SANTA CRUZ - Arrestan a dos personas por
venta de ivermectina con precio sextuplicado - 29 June 2020 -   http://archive.vn/GWW7f and also
Ivermectin trafficking - "Dois homens são flagrados com 250 caixas de ivermectina contrabandeada
da Bolívia em MT [Mato Grosso]; remédio é usado contra Covid-19 - Além de ivermectina, eles
também contrabandearam 25 caixas de levofloxacino hemi- hidrato, nove caixas de Paracetamol e
14 caixas de Ibuprofeno. Toda a mercadoria está avaliada em R$ 8 mil.  - 29/06/2020 10h51  -
http://archive.vn/K4pLG
The Gorvernor of  Mato Grosso  - “Não tomei cloroquina. Nada contra, mas ... ”. O governador
afirmou  que  fez  uso  de  dois  comprimidos  de  Ivermectina  por  um dia.  O remédio  é  um anti-
helmíntico  (vermífugo),  que  em  estudo  in  vitro  teria  demonstrado  capacidade  de  reduzir  a
duplicação do vírus e impedir a entrada dele nas células. No entanto, poucas evidências demonstram
sua eficácia". 09/06/2020 -  http://archive.vn/sHWX5
Once more we find - On Jul 7, 2020 - "Animal products not intended for COVID-19 treatment" -
https://www.kmaland.com/ag/animal-products-not-intended-for-covid-19-treatment/article_a7e78cdd-c7df-
572c-8a95-2f1194761e52.html - archived http://archive.vn/aWjsQ - "As the public became aware of the
research paper there were growing concerns about people wanting ivermectin to treat COVID-19 --
and self-medicating by taking ivermectin products intended for animals".
"Latin America is battling some of the world's most devastating coronavirus outbreaks, and is also
facing the scourge of fake cures and unproven treatments  promoted on social  media across the
region."  12  July  2020  -  https://www.bbc.com/news/53361876 -  "Along  with  many  other  drugs,
ivermectin's effectiveness against Covid is being evaluated in clinical trials. But the PAHO has said
studies so far "were found to have a high risk of bias, very low certainty of the evidence, and that
the existing evidence is insufficient to draw a conclusion on benefits  and harms. Ivermectin "is
incorrectly  being  used  for  the  treatment  of  Covid-19"  says  the  PAHO, "without  any scientific
evidence of its efficacy and safety for the treatment of this disease". Despite this, health officials in
Peru, Bolivia and parts of Brazil have endorsed and administered the drug - and it has been widely
sold".
In the Section 6, we have already seen that Dr. Alam reported of results on the use of Ivermectin.
Here further  news - Dr Tarek Alam: Unleashing the potential of Ivermectin - UNB NEWS DHAKA
PUBLISH- JULY 19, 2020, 12:22 PM  - https://unb.com.bd/category/special/dr-tarek-alam-unleashing-the-
potential-of-ivermectin/54846 - archived http://archive.is/XFQLe .  For Covid-19, as we have previously
seen, it was used a combination of "two cheap, easily available drugs". The article tells that the
combination of drugs eas success in reducing the viral load and restricting the severity of disease.
"Apparently 98 percent of Covid-19 patients get cured with the combined use of anti-parasitic drug
Ivermectin and antibiotic Doxycycline within 4-14 days, said Dr Tarek Alam, the renowned doctor
who has been leading a team of BMC physicians in a study during the course of treating patients at
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the  hospital  attached  to  BMC.  They  recently  reported  tremendous  success  with  the  two-drug
combination treatment against the virus during its study that started on April 15 last.  “What we’ve
found is that it’s better to use the two drugs as soon as possible after a person is tested positive or
symptom is seen,” Dr Alam said in a virtual interview with UNB.  “We used the drugs within 5-6
days on all patients (and almost all got cured). Actually it needs to conduct further study whether
these (drugs) will be effective in case of use after the time,” he said, adding that so far the drugs
have been used on “some 400-500 Covid patients” since April.  But only “4-5 patients” having
diabetes and heart problems or who delayed in getting the treatment needed to go to Intensive Care
Unit  (ICU).  And  two  patients  died  despite  being  administered  with  Remdesivir  and  plasma
therapy". 
16 - Not all doctors 
Let us go back to news from Peru. As we have previously seen, there is a health movement - as
defined by TrialSite - in Peru, driven by physicians. From news we known that it is supported by
the Government. However,  some  "Médicos peruanos piden detener el uso de la hidroxicloroquina
e  ivermectina  en  pacientes  COVID-19"  -  30  June   2020  ----------------------
https://larepublica.pe/sociedad/2020/06/29/coronavirus-peru-medicos-piden-detener-el-uso-de-la-
hidroxicloroquina-e-ivermectina-en-pacientes-covid-19-carta-abierta-al-minsa/  ,  http://archive.vn/YbsuR -
"Los doctores ... se mostraron preocupados por el uso de la hidroxicloroquina y la ivermectina que
impulsan  las  autoridades  sanitarias  en  el  país  como  tratamiento  para  la  COVID-19".  This  is
important. And also here  https://www.estrelladigital.es/articulo/america/medicos-peruanos-piden-detener-
uso-hidroxicloroquina-ivermectina-pacientes-covid-19/20200630102348422556.html archived
http://archive.is/7UAD0 - "Los doctores Julio Chirinos, médico internista y cardiólogo (Universidad
de Pensilvania), Vicente Corrales, médico internista e infectólogo (The Ottawa Hospital) y Germán
Málaga, médico internista (Universidad Peruana Cayetano Heredia) se mostraron preocupados por
el uso de la hidroxicloroquina y la ivermectina que impulsan las autoridades sanitarias en el país
como tratamiento para la COVID-19. Los especialistas precisaron que ambos medicamentos son
recomendados por el Minsa, pero numerosos estudios de importante credibilidad han reportado una
falta de efectividad por parte de los fármacos cuando se aplican con la finalidad de tratar la COVID-
19. Tras haber difundido la misiva el pasado 17 de junio, el grupo de galenos no ha obtenido una
respuesta  concreta,  pero  confía  en  que  establecerá  un  diálogo  oficial  y  sincero  con  los
representantes de la cartera ministerial".
The  Carta  Abiertas  is  available  at https://it.scribd.com/document/466257700/Carta-Abiertas-sobre-las-
recomendaciones-del-MINSA-sobre-el-tratamiento-con-medicamentos-de-COVID-19-en-el-
Peru#from_embed
17 - US monopolises Remdesivir
A very interesting discussion - US monopolises COVID-19 treatment drug. Which countries are
missing  out?  -  https://www.sbs.com.au/news/dateline/us-monopolises-covid-19-treatment-drug-which-
countries-are-missing-out (web site visited 8 July 2029) - "The US has bought most of the globes’
supply of remdesivir, an antiviral drug that could help treat COVID-19. The Trump administration
has purchased more than 500,000 doses of remdesivir -- that’s almost all of the world’s supply for
the next three months. The antiviral could help treat COVID-19 by improving the recovery time for
hospitalised patients. It is not a cure". About Peru it is told - "Unless the country has its own stocks
of remdesivir,  it’s  unlikely  Peru will  have access  to  the drug in  the next  months.  Last  month,
officials spruiked ivermectin, an antiparasitic commonly used in tropical medicine, as a COVID-19
treatment.  The  Pan  American  Health  Organization,  a  regional  office  of  the  World  Health
Organization, has issued a statement warning against the use of ivermectin to treat COVID-19. The
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Peruvian Ministry of Health also promoted hydroxychloroquine has an effective treatment". If US
possesses Remdesivir - if it is useful or not is another problem -  what can the rest of humankind
use?
18 - From Bulgaria, India and Brazil
On  July  6,  2020  -  "Bulgarian  Team  Close  to  Finding  a  Treatment  for  COVID-19"  -
https://www.novinite.com/articles/205180/Bulgarian+Team+Close+to+Finding+a+Treatment+for+COVID-
19 , archived  http://archive.vn/EBN7l    - "In May, a clinical trial  with the drug Ivermectin was
launched in Bulgaria.  The team is Bulgarian,  and so is the manufacturing company. So far, 30
patients have been recruited for it. The clinical trial is being conducted in 9 hospitals in Bulgaria,"
Kirilov [director  of Bulgarian Drug Agency] said. "Bulgaria was the first  country in the EU to
launch such a clinical  trial,  followed by Spain,  Brazil  and the United States.  We hope to have
primary results by the end of the month." "
7 July 2020 - "Grupo de 478 médicos do DF elabora protocolo para tratamento precoce da Covid-19
Documento  com  sugestão  de  medicamentos  foi  entregue  à  Secretaria  de  Saúde  e  inclui
hidroxicloroquina e ivermectina" -  https://www.metropoles.com/colunas-blogs/grande-angular/grupo-de-
478-medicos-do-df-elabora-protocolo-para-tratamento-precoce-da-covid-19 -  "Um   grupo  com  478
médicos da rede pública e privada do Distrito Federal se reuniu para elaborar e propor um protocolo
de tratamento precoce de pacientes infectados pelo novo coronavírus. Na lista de medicamentos a
serem  ofertados  aos  doentes  está  a  hidroxicloroquina,  além  do  vermífugo  ivermectina  e  do
antibiótico azitromicina. ... “Temos medicações que estão disponíveis, são de baixo custo, baixa
toxicidade e que podem ser prescritas pelos médicos no primeiro estágio da Covid-19 para diminuir
a replicação viral. É claro que todos nós gostaríamos de trabalhar com base em estudos científicos
sólidos. Mas vivemos uma situação atípica, de guerra. O novo coronavírus não está na bula, porque
ele não existia quando os medicamentos foram criados”,  explica a otorrinolaringologista Carine
Petry, uma das integrantes do grupo.
On  3  July  2020  -  https://www.nationalheraldindia.com/india/delhis-ln-hospital-to-discontinue-anti-viral-
drug-favipiravir-for-covid-19-treatment - "Delhi’s LN Hospital  decides against using anti-viral drug
Favipiravir for COVID-19 treatment. The LN Hospital committee approved the use of three other
drugs – Remdesivir, Tocilizumab and Ivermectin – and plasma therapy in the treatment of COVID-
19. ... The committee acknowledges that though Ivermectin has shown only laboratory evidence as
an inhibitor  of the COVID-19 causative  virus,  it  should be considered for hospitalised patients
because it is a cheap drug, easily available and is known to be safer than other drugs. Its side effects
are only fever and skin rash. This drug, which has been approved by the US FDA for parasitic
infections, could help in limiting the viral load and prevent severe disease progression, according to
the doctors at LN Hospital".
19 - a - SSRN or Antiviral Research
As we have previously seen, a working paper was published in SSRN  and then retracted by the
authors. For this reason, I have not discussed it above.  In Google Scholar it appears as "Ivermectin
in  COVID-19 related  critical  illness,  SSRN 3570270,  2020 -  papers.ssrn.com -  "A pre-clinical
study, demonstrated that ivermectin, FDA approved as an anti-parasitic agent with an established
safety profile …". I repeat, the paper was withdrawn from SSRN by the authors.  However, we have
to mention SSRN for the following news.
5  July  2020 -  "San  Marcos:  tratamiento  con  ivermectina  tiene  menos  tasa  de  letalidad"  -
https://www.radionacional.com.pe/noticias/locales/san-marcos-tratamiento-con-ivermectina-tiene-menos-
tasa-de-letalidad - La tasa de letalidad en los pacientes que usaron ivermectina en su tratamiento
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contra el covid-19 fue 6.1 veces menor en comparación con los pacientes que no lo usaron, según
un estudio realizado por el médico egresado de la Universidad Nacional Mayor de San Marcos
(UNMSM),  Gustavo  Aguirre".  The  same  in  http://laindustria.pe/nota/16663-tratamiento-con-
ivermectina-tiene-menos-tasa-de-letalidad and  in  https://libero.pe/ocio/1570733-coronavirus-peru-estudio-
revela-100-pacientes-covid-19-trato-ivermectina-mejoraron-minsa -  After  two  days  -  7  July  2020  -
"Ivermectina y COVID-19: los errores y mentiras detrás de un “estudio” viral de dudosa calidad" -
https://elcomercio.pe/tecnologia/ciencias/ivermectina-covid-19-coronavirus-los-errores-y-mentiras-detras-
de-un-estudio-viral-de-dudosa-calidad-noticia/ . 
The  elcomercio.pe  is  not  giving  links  to  documents.  However,  it  seems  -  due  to  published
screenshot -  it is the same of that at http://archive.is/x12Co ). The elcomercio.pe tells the research
"había sido publicada en Antiviral Research. El Comercio comprobó que el estudio no figura en
esta revista médica internacional". In the document, Dr. Aguirre Chang does not tell that his work
has been published in the Antiviral Research journal. The document seems being a working paper.
In any case,  let us stress that the paper published in the Antiviral Research journal is Ref.
[CAL1]. In Aguirre's working paper (http://archive.is/x12Co), there was a mistake in abstract and
text. It was told that the document in SSRN has been placed on the web site of Antiviral Research6.
This mistake raised confusion, enhanced by elcomercio in the news.  SSRN working paper is no
more available, because it has been withdrawn. Let us forget it, but ask for results obtained by
physicians that used ivermectin.
It seems to me that Aguirre's document to consider is [AGU1]. "RESULTADOS:  Se  trataron  con
Ivermectina  33  pacientes adultos con  Síntomas Persistentes de COVID-19. En el 97% de los 33
pacientes  tratados  con  Ivermectina  se  encontró  mejoría  clínica  después  de  las  2  dosis  de
Ivermectina. La mejoría clínica fue total en el 87.9% de los pacientes después de la 2da dosis de
Ivermectina. En el 12.1% de los pacientes se requirió dar más días de tratamiento con Ivermectina,
pero con esto se logró una mejoría clínica y remisión de los síntomas en el 100% de los casos.
CONCLUSIÓN: El   resultado   del   presente   estudio   encuentra   efectividad   del tratamiento con
Ivermectina de los pacientes con Síntomas Persistentes de COVID-19, observándose una mejoría
clínica en el 100% de los casos".
As we have previously told, Dr. Aguirre is reporting, in the previously mentioned documents, of
several  cases  in  Peru.  We  are  also  waiting  for  the  report  of  Dr.  Elera,  as  he  promised  to
elcomecio.pe (see the news previously mentioning him) and from all the other doctors engaged in
the Health Movement. The reason is the following: to test the efficacy of ivermectin. 
19 - b - Un breve commento sul documento in SSRN, ora ritirato
Il lavoro pubblicato su SSRN (16 Aprile) ed ora ritirato, autori con affiliazioni negli Stati Uniti,
sosteneva l'efficacia  dell'ivermectina in pazienti  ricoverati  per Covid-19 in terapia  intensiva.  Lo
studio era retrospettivo tra il primo Gennaio del 2020 ed il 31 Marzo del 2020. Si dice che si sono
analizzati  in Europa 107+120=227 casi.  Guardate i dati  delle vittime in Italia,  Francia,  Spagna,
Regno Unito. Vi sembra possibile che in Europa, avendo ottenuto in qualche caso buoni risultati
con l'ivermectina, essa non sia stata usata per evitare le stragi da Covid-19? Pensate a questo.  In
ogni caso, i dati non potevano provenire dall'Italia, dove, secondo le notizie, solo da Aprile, nello
specifico l'8 Aprile, si sarebbe autorizzato l'uso dell'ivemectina in test clinici, a seguito della ricerca
pubblicata in [CAL1].
The work published on SSRN (April 16) and now withdrawn, authors with affiliations in the United
6 Aguirre-Chang has revised the text. The new version is at https://www.researchgate.net/publication/342466502
       _INCLUSION_DE_LA_IVERMECTINA_EN_LA_PRIMERA_LINEA_DE_ACCION_TERAPEUTICA_PARA_COVID-
19_Se_reporta_una_muy_significativa_disminucion_de_la_Tasa_de_Letalidad_con_su_uso - See also 
http://archive.is/vwHOs
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States, supported the efficacy of ivermectin for patients in hospital intensive care units for Covid-
19. The study was retrospective, between 1 January 2020 and 31 March 2020. 107 + 120 = 227
cases are said to have been analysed as coming from Europe. Look at the data of the victims in
Italy,  France,  Spain,  and in the United Kingdom. Does it seem possible to you that in Europe,
having in  some cases obtained good results  with ivermectin,  it  has not  been used to  avoid the
massacres of Covid-19? Think about this.  In any case, data  could not come from Italy,  where,
according to the news, the use of ivermectin in clinical trials was authorized just from April, the 8
of April, after the results published in [CAL1].
In my opinion, but I have to check it, ivermectin was not used in Europe to treat Covid-19 from the
first of January to the end of March, not used at all. Therefore, I want to tell once more to forget
this  damned  SSRN preprint.  There  is  no  point  in  the  news  continuing  to  bring  it  up.  Let  us
concentrate on the results obtained by physicians who are using ivermectin.
20 - Rare symptoms of Covid-19 - a report from Dr. E. Durand, Lima
As previously told, ivermectin has a large use in Peru. This fact gives the possibility to receive
specific reports from physicians about the efficacy of it in the treatment of Covid-19 patients. At the
same time, these reports can evidence new facts about the disease and consequently improve the
knowledge about the effects of Sars-Cov-2 on human bodies. Here in the following an important
example. 
"Perú:  médico  que  ha  tratado  más  de  3,000  pacientes  de  coronavirus  reporta  raro  síntoma  en
mujeres  y  confirma  eficacia  de  la  ivermectina"  -  Lima,  Peru  -  27  Julio  2020  -
https://www.connuestroperu.com/ciencia-y-tecnologia/salud/66246-peru-medico-que-ha-tratado-mas-de-3-
000-pacientes-de-coronavirus-reporta-raro-sintoma-en-mujeres-y-confirma-eficacia-de-la-ivermectina  -------
archived http://archive.is/YKGWv
"Un síntoma raro ha sido observado en pocos pacientes contagiados con el coronavirus COVID-19
en Lima y se presenta en mujeres.  El doctor Eduardo Durand, quien ha atendido en la práctica
privada  a  más  3,000   pacientes  con  coronavirus,  reporta  síntomas   raros  en  pocos  pacientes.
Consisten  en  debilidad  de  los  miembros  inferiores  acompañada  de  dolor  lumbar,  que  hasta  el
momento ha observado en cinco pacientes mujeres. El galeno, de Consultorios Médicos San Luis,
Lima,  señala  que  junto  con estos  síntomas,  las  pacientes  presentaron  también   dolor  de  oído,
sensación de frío en la espalda y ardor en los ojos. Las pacientes,  de edades de 30 a 65 años,
pasaron por  análisis  de  prueba  rápida  y radiografía  de tórax.  Todas  recibieron  tratamiento  que
resultó satisfactorio con su recuperación gradual en un promedio de diez días."
Rare symptoms have been observed in few Covid-19 patients in Lima and occurred in women.
Dr.  Eduardo Durand,  who  has  treated  more  than  3,000 patients  with  coronavirus  in  his
private practice, reports about them. The symptoms consist of weakness of the lower limbs
accompanied by low back pain, which have been observed in five female patients so far. Dr.
Durand, Consultorios Médicos San Luis, Lima, pointed out that, along with these symptoms,
the patients  also presented ear pain,  a feeling of cold in the back and burning eyes.  The
patients, aged 30 to 65 years, underwent rapid test analysis and chest radiography. They all
received a treatment that was effective for their gradual recovery in an average of ten days.
The reports continues about ivermectin. "Eficacia de la ivermectina - El doctor Durand destaca la
eficacia de la ivermectina y considera a este fármaco un gran y rápido aliado, y destaca su fácil
accesibilidad.  Tanto  las  pacientes  con  estos  síntomas  raros,  como  más  de  tres  mil  pacientes,
superaron la enfermedad en estados leve a moderado, a los cuales prescribió de una a dos gotas de
ivermectina  por  kilo  de  peso,  según  el  grado  de  complicación,  sin  haberse  observado  efectos
28
adversos, salvo un caso de diarrea. Recomendación a la ciudadanía ante el aumento de contagios y
fallecimientos. El galeno recomienda a la ciudadanía estar alerta a los síntomas de esta enfermedad
y no dejar que avance, pues puede requerir hospitalización en un momento en que los hospitales
están saturados. De igual forma, no deje pasar el tiempo con calmantes. Indica que si en la zona en
que se encuentra no hay pruebas de descarte, deje que con diagnóstico de síntomas su médico inicie
el tratamiento,  pues por televisión se ve a personas esperando días por la  prueba sin inicio de
tratamiento, con lo cual van camino al agravamiento porque es una enfermedad que avanza a gran
velocidad."
Eduardo Durand highlights the efficacy of ivermectin  and considers this drug a great and fast
allied agent, of easily availability, against Covid-19. The patients with rare symptoms, such as his
other  Covid-19 patients  -  more than 3,000 -,  overcame the disease in  mild to  moderate  states.
Ivermectin  was  prescribed  according  to  the  state  of  patient. Adverse  effects  have  not  been
observed,  except  for  a  case  of  diarrhea. Actually,  Dr.  Durand  recommends  not  letting  the
symptoms of the disease progress, in order to avoid hospitalization. In the case that it is not possible
to test for Sars-Cov-2 infection, when symptoms are observed, it is better to ask a doctor for starting
a treatment as soon as possible to avoid the aggravation of the disease. Covid-19 is a disease that
progresses rapidly.
The rare symptoms observed and reported by Dr. E. Durand, Consultorios Médicos San Luis, Lima,
Peru,  have  to  be added to  the  list  of  the  neurological  associations  of  the  disease  published in
[ELL1].
21 - Making ivermectin for oral use (6mg/mL)
As we have discussed before (see Section 13), it happened that ivermectin for veterinary use had
been  injected  in  many  persons  with  Covid-19.  In  fact,  ivermectin  for  parenteral  route  of
administration is existing only in the veterinary formulation. The use of this formulation in rescue
therapy is effective and safe,  according to publications. In fact, the drug for veterinary use must be
safe,  because  accidental  self-injection  and  ingestions  are  possible.  See  cases  in
http://archive.is/awBXE .  Ivermectin  is  generally  well  tolerated.  "Only  side  effects  have  been
reported:  itching, swollen lymph glands, dizziness,  hypotension,  fever,  headache and myalgia.
Side effects are more frequent and severe in patients with high microfilaria counts. Other persons at
risk  include  veterinarians  and  farm  workers  involved  in  treating  animals  for  worms  and
ectoparasites.   Most  cases  reported  involve  accidental  self-injection  and  some  ingestions  of
injectable solutions. No human deaths have been  reported".
However, some web sites of newspapers raised concerns about the use of ivermectin for parenteral
route of administration, in particular elcomercio.pe as we have seen. On 28 June, the same web site
gives  the  important  news.  https://elcomercio.pe/peru/coronavirus-peru-san-martin-essalud-moyobamba-
comenzo-a-producir-ivermectina-con-capacidad-de-20-mil-dosis-mensuales-nnpp-noticia/ ,  we  read  that
ivermectin for oral use is produced in a local hospital. "Una excelente noticia para la región San
Martín dio a conocer EsSalud-Moyobamba, tras anunciar que viene produciendo ivermectina para
el tratamiento de pacientes con COVID-19, a cargo del área de Farmacotecnia del Hospital II-1 Alto
Mayo que está en capacidad de elaborar 20 mil dosis mensuales. ... Asimismo, la composición de
ivermectina incluye alcohol etílico, propilenglicol, sorbitol e ivermectina de uso médico (sólido), y
será suministrado bajo prescripción médica". The same, that is the production of ivermectin for oral
use to treat Covid-19, is happening in other hospitals is Peru.
In fact, a document dated 23 June 2020 of the Peruvian Government exists which is giving the
formulation. https://cdn.www.gob.pe/uploads/document/file/874053/RM_426-2020-MINSA.pdf
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Formulation from MINSA, Peru.
22 - Data
As we can appreciate in the news from Peru - and South-America, in general - it seems that a large
use of ivermectin is and will be made for Covid-19. It is therefore clear that an efficacy of the drug
can be easily evidenced by the numbers about new, active cases and victims in the country. In the
plots given below, proposed by the www.worldometers.info for Peru, it is reasonable to imagine
that the curves, about new and active cases, and victims, can be influenced by any efficacy of the
drug.
Fig.4 - Daily New Cases. The blue  line represents a 7-days moving average.
Fig.5  - Number of infected people (active cases).
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Fig.5 - Daily victims.  Red line represents a 7-days moving average.
The data (15 February - 27 July,  are a courtesy of worldometers.info, available at 
https://www.worldometers.info/coronavirus/country/peru.
The number of the daily cases is increasing, but the number of victims of the virus seems to have a 
decreasing trend in the last days of July.
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Appendix A
Not only ivermectin is under investigation. 16 June 2020 - "Broad-Spectrum Antiparasitic Drug
Ivermectin  Could  Help  `Cure`  COVID-19"  is  told"  by  https://www.hospimedica.com/covid-
19/articles/294782974/broad-spectrum-antiparasitic-drug-ivermectin-could-help-cure-covid-19.html
archived  http://archive.vn/mOV0b -  The article  is  reporting  about  the  clinical  trial  led  by   Eli
Schwartz,  Sheba  Medical  Center  (Tel  Hashomer,  Israel).  But  it  is  also  telling  the  following.
"Another anti-parasitic drug niclosamide tested on ferrets in a study by Daewoong Pharmaceutical
Co.,  Ltd.  (Seoul,  Korea)  was found to have eliminated  the novel  coronavirus from their  lungs.
According to Daewoong, its experimental anti-viral drug completely cleared up the disease in the
lung tissues of ferrets and the company now plans to start human clinical trials in July with approval
of the COVID-19 treatment drug expected by the end of this year". Niclosamide is nentioned in trial
https://ClinicalTrials.gov/show/NCT04345419 .
In [XIN1], a study of possible drugs against Sars-Cov-2, it is told "Interestingly, three anti-parasitic
drugs pyrvinium, ivermectin, and niclosamide were ranked among the top 30 predicted drugs. Both
ivermectin and niclosamide were shown to inhibit the replication of SARS-CoV-2 in vitro (Caly et
al.  2020; Jeon et  al.  2020), and pyrvinium and niclosamide were shown to be effective against
MERS-CoV and SARS-CoV (Shen et al. 2019; C.-J. Wu et al. 2004)".
In [KAN1], it is told: "Niclosamide: Another medication undergoing repurposing investigations for
SARS‐CoV‐2 is niclosamide, an oral anthelmintic drug used worldwide at a single dose of 2 g/d.
Niclosamide exerts anti‐MERS activity, inhibits SARS‐CoV replication and abolishes viral antigen
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synthesis in vitro, (Refs. 51,52 of [KAN1]) and therefore, is considered a possible treatment option.
However,  it  is  cytotoxic  and  has  low absorption  including  low oral  bioavailability  (10%) and
although efforts have been made to formulate derivatives to overcome these obstacles, its extensive
clinical development as an antiviral agent may still be hindered. An interventional trial has been
registered to evaluate the use ...". As we have told before, Ivermectin is safe. 
See also Ref. [PAU1]: "Clinical trials on the repurposing of some  anthelmintics (Nitazoxanide,
NTZ;  Ivermectin,  IVT;  Niclosamide,  NCL)  for  COVID-19 seem to  be  based  on in  vitro  data
showing that these compounds inhibit replication of a variety of viruses in cell culture assays. NTZ,
for instance, was active in cell culture assays against a broad range of influenza A and B, as well as
other  RNA  and  DNA  viruses,  such  as  RSV,  parainfluenza,  coronavirus,  rotavirus,  norovirus,
hepatitis B and C viruses, dengue, yellow fever, Japanese encephalitis and HIV. Likewise, in in
vitro tests, IVM inhibited the replication of a broad range of viruses (dengue, West Nile virus, HIV,
simian SV-40, influenza and others) and strongly repressed SARS-CoV-2 virus replication in Vero-
hSLAM  cells.  Also  in  in  vitro  assays,  NCL  proved  to  be  a  potent  inhibitor  (nanomolar  to
micromolar  range)  of  replication  of  SARS-CoV, MERS-CoV, zika  virus,  hepatitis  C virus  and
human  adenovirus.  NCL  had  been  reported  to  be  active  (in  vitro)  against  SARS-CoV  at
concentrations as low as 1.56 µM in 2003". See also [JXU1] , [POO1].
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